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1				Abstract	
	
Understanding	 the	 transcriptional	 mechanisms	 that	 control	 hematopoiesis	 and	 the	
interaction	 between	 hematopoietic	 stem	 cells	 and	 the	 bone	 marrow	 (BM)	
microenvironment	in	vivo	is	of	considerable	interest.	
	The	 calcineurin‐dependent	 transcription	 factor	 NFAT	 (Nuclear	 Factor	 of	 Activated	 T	
cells)	 is	 known	 as	 master	 regulator	 of	 cytokine	 production	 in	 T	 lymphocytes	 and	
therefore	 central	 for	 T	 cell‐dependent	 immune	 reactions,	 but	 has	 also	 been	 shown	 to	
regulate	a	process	of	differentiation	and	tissue	adaptation	in	various	cell	types.	
The	activation	of	NFAT	is	dependent	on	the	calcium	level	within	the	cell.	In	resting	cells,	
calcium	levels	are	low	and	NFAT	is	cytoplasmic	and	inactive.	A	sustained	increase	in	the	
internal	 calcium	 concentration	 within	 an	 external	 stimuli	 leads	 to	 activation	 of	 the	
calcium‐dependent	 calcineurin,	 followed	 by	 dephosphorylation	 and	 nuclear	
translocation	of	NFAT.		
We	have	previously	shown	that	NFATc2,	a	member	of	the	NFAT	family,	is	expressed	in	
CD34+	 hematopoietic	 stem	 cells	 (HSC).	 A	 mouse	 model	 harboring	 NFATc2	 deficiency	
provides	 the	 opportunity	 for	 in	 vivo	 investigation	 of	 the	 role	 of	 NFATc2	 in	
hematopoiesis.		
Our	recent	observations	showed	that	aged	mice	lacking	the	transcription	factor	NFATc2	
develop	 peripheral	 blood	 anemia	 and	 thrombocytopenia,	 BM	 hypoplasia	 and	
extramedullary	hematopoiesis	in	spleen	and	liver.	The	proliferation	and	differentiation	
of	NFATc2‐deficient	hematopoietic	stem	cells	ex	vivo,	however,	was	found	to	be	intact.	It	
remained	 therefore	unclear	whether	 the	disturbed	hematopoiesis	 in	NFATc2‐deficient	
mice	 was	 caused	 by	 the	 hematopoietic	 or	 the	 stroma	 component	 of	 the	 BM	
hematopoietic	niche.		
In	the	current	study	we	dissected	the	relative	contribution	of	hematopoietic	and	stroma	
cells	 to	 the	 phenotype	 of	 the	 NFATc2‐deficent	 mice	 by	 transplanting	 immuno‐
magnetically	purified	NFATc2‐deficient	(KO)	HSCs	to	lethally	irradiated	wild	type	(WT)	
mice,	 and	 vice	 versa.	 After	 a	 post‐transplantation	 period	 of	 6‐8	 months,	 peripheral	
blood,	 BM	 as	well	 as	 spleen	 and	 liver	 of	 the	 transplanted	 animals	were	 analyzed	 and	
compared	to	WT	and	KO	mice	transplanted	with	control	cells.			
Abstract	
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Transplantation	 of	 NFATc2‐deficient	 HSCs	 into	 WT	 recipients	 (KOWT)	 induced	
similar	hematological	abnormalities	as	those	occurring	in	non‐transplanted	KO	mice	or	
in	KO	mice	 transplanted	with	KO	 cells	 (KOKO).	 Compared	 to	WT	mice	 transplanted	
with	WT	cells	(WTWT),	KOWT	mice	showed	evidence	of	anemia,	thrombocytopenia	
and	 a	 significantly	 reduced	 number	 of	 hematopoietic	 cells	 in	 their	 BM.	 Likewise,	
KOWT	 mice	 developed	 clear	 signs	 of	 extramedullary	 hematopoiesis	 in	 spleen	 and	
liver,	which	was	not	the	case	in	WT		WT	control	animals.		
In	addition	to	the	hematopoietic	abnormalities,	transplantation	of	NFATc2‐deficient	HSC	
also	 induced	 osteogenic	 abnormalities	 such	 as	 BM	 sclerosis	 and	 fibrosis	 in	WT	mice.		
This	 phenomenon	was	 rather	 subtle	 and	 of	 incomplete	 penetrance,	 but	 never	 seen	 in	
mice	transplanted	with	WT	cells.	
These	data	demonstrate	for	the	first	time,	that	the	NFATc2	transcription	factor	directly	
regulates	 the	 intrinsic	 function	 of	 hematopoietic	 stem	 cells	 in	 vivo.	 However,	 the	
transcriptional	targets	for	NFAT	in	these	cells	are	yet	unknown.	
In	addition	 to	hematopoietic	 stem	cells,	NFATc2	has	been	 shown	 to	be	expressed	 in	a	
lineage‐specific	 manner	 during	 myeloid	 differentiation	 and,	 notably,	 is	 maintained	
during	 megakaryopoiesis	 while	 it	 is	 suppressed	 during	 the	 differentiation	 of	
neutrophils.	 Bone	 marrow	 megakaryocytes	 are	 the	 precursors	 of	 peripheral	 blood	
platelets	 and	 therefore	 constitute	 an	 integral	 part	 of	 primary	 hemostasis,	 thrombosis	
and	wound	healing.	The	biological	role	of	NFAT	in	megakaryocytes	is	unknown.	
We	 have	 recently	 shown	 that	 NFATc2	 is	 not	 necessary	 for	 megakaryocytic	
differentiation.	On	the	other	hand,	recent	evidence	suggests	that	NFATc2	is	required	for	
the	transcription	of	specific	megakaryocytic	genes.		
In	 this	 study,	 we	 showed	 that	 activation	 of	 the	 calcineurin/NFAT	 pathway	 in	 either	
primary	 megakaryocytes	 or	 CMK	 megakaryocytic	 cells	 forces	 the	 cells	 to	 go	 into	
apoptosis.	Cell	death	in	megakaryocytes	is	induced	by	treating	the	cells	with	the	calcium	
ionophore	 ionomycin	and	suppressed	by	either	 the	pan‐caspase	 inhibitor	zVAD	or	 the	
calcineurin	 inhibitor	 cyclosporin	 A	 (CsA).	 Ionomycin	 stimulation	 of	 megakaryocytes	
leads	 to	 the	 expression	 of	 Fas	 Ligand	 (FASLG),	 a	 pro‐apoptotic	member	 of	 the	 tumor	
necrosis	factor	superfamily.	Expression	of	FASLG	was	detectable	as	early	as	four	hours	
after	 stimulation	 on	 the	 membrane	 of	 ionomycin‐treated	 megakaryocytes,	 was	
augmented	 in	 cells	 stably	 overexpressing	NFATc2,	 and	was	 suppressed	 in	 cells	 either	
Abstract	
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pretreated	 with	 CsA	 or	 expressing	 the	 specific	 peptide	 inhibitor	 of	 NFAT,	 VIVIT.	 To	
investigate	 the	 physiological	 relevance	 of	 FASLG	 expression	 on	 megakaryocytes,	 we	
performed	co‐cultures	of	megakaryocytes	with	Fas‐expressing	T‐lymphocytes,	in	which	
CMK	 cells	 were	 left	 either	 unstimulated	 or	 pre‐stimulated	 with	 ionomycin	 and	 then	
added	 to	 Jurkat	 cells.	 The	 presence	 of	 ionomycin‐stimulated	 CMK	 cells,	 but	 not	 of	
unstimulated	 cells	 or	 cells	 stimulated	 in	 the	 presence	 of	 CsA,	 significantly	 induced	
apoptosis	in	Jurkat	cells.	Overexpression	of	NFATc2	in	CMK	cells	enhanced	their	potency	
to	 induce	 apoptosis	 in	 Jurkat	 cells,	 while	 cells	 expressing	 VIVIT	 were	 less	 effective.	
Apoptosis	induction	of	Jurkat	cells	by	stimulated	CMK	cells	was	partially	blocked	by	the	
presence	of	either	a	neutralizing	antibody	against	FASLG	or	an	antagonistic	antibody	to	
Fas	 during	 the	 co‐culture	 period,	 indicating	 involvement	 of	 the	 FASLG/Fas	 apoptosis	
pathway.				
These	 results	 represent	 the	 first	 clear	 evidence	 for	 a	 biological	 function	 of	 the	
calcineurin/NFAT	 pathway	 in	 megakaryocytes,	 namely	 the	 regulation	 of	 Fas/FASLG‐
dependent	apoptosis.	Second,	they	underline	that	the	biological	role	of	megakaryocytes	
is	not	restricted	to	the	production	of	proteins	and	other	cellular	structures	for	platelet	
assembly,	but	that	this	population	of	cells	fulfills	an	independent	regulatory	function	in	
the	context	of	the	surrounding	tissue.		
Finally,	 we	 have	 identified	 by	 RNA	 sequencing	 analysis	 of	 NFATc2‐expressing	 and	 ‐
deficient	 cells,	 the	 entire	 set	 of	 genes	 which	 is	 induced	 by	 NFATc2	 in	 stimulated	
megakaryocytes.	 Functional	 pathway	 analysis	 suggests	 an	 involvement	 of	 NFATc2	 in	
pro‐inflammatory	pathways	 in	 these	 cells.	The	 significance	of	 these	 findings	has	 to	be	
addressed	in	further	studies.	
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2	 Introduction	
2.1	 Nuclear	Factor	of	Activated	T	cells		
2.1.1	 NFAT	transcription	factors	
	
Nuclear	 factor	 of	 activated	 T	 cells	 (NFAT)	 is	 primarily	 known	 as	 an	 inducible	
transcription	 factor	 in	 activated	 T	 cells.1	 However,	 isolation	 and	 molecular	
characterization	 of	 NFAT	 family	 members	 revealed	 that,	 despite	 their	 names,	 NFAT	
expression	is	not	restricted	to	T	cells.	In	fact,	NFAT	proteins	have	been	identified	in	cells	
of	non‐immune	system	as	well	 as	 the	other	 cells	of	 the	 immune	system.2‐5	 	Therefore,		
the	role	of	 	NFAT	proteins	was	 investigated	in	the	regulation	of	other	cells	and	tissues	
outside	 of	 the	 immune	 system,	 including	 skeletal	 muscle	 and	 cardiac	 hypertrophy,6‐8	
cardiac	valve	morphogenesis,9‐11	angiogenesis,10,	 12,	 13	bone	tissue	including	osteoblasts	
and	 osteoclasts,14‐16	 chondrocytes,17,	 18	 keratinocytes,19,	 20	 adipocytes,21,	 22	 axonal	
outgrowth	of	neurons.23	
The	family	of	NFAT	transcription	factors	consists	of	five	proteins:	NFAT1	(also	known	as	
NFATc2	or	NFATp),	NFAT2	(also	known	as	NFATc1	or	NFATc),	NFAT3	(also	known	as	
NFATc4),	 NFAT4	 (also	 known	 as	 NFATc3	 or	 NFATx)	 and	 NFAT5	 (also	 known	 as	
enhancer	binding	protein	TonEBP).	NFAT	family	members	evolutionarily	belong	to	the	
REL‐nuclear	factor‐κB	(REL–NF‐κB)	family	of	transcription	factors.3,	24,	25	NFAT	proteins	
contain	 an	 amino‐terminal	 transactivation	 domain	 (TAD),	 a	 regulatory	 domain	 (also	
known	 as	 the	NFAT	homology	 region,	NHR),	 a	 highly	 conserved	DNA‐binding	 domain	
(also	known	as	the	Rel‐homology	domain,	RHD)	and	a	carboxy	terminal	domain	(figure	
2.1).4,	 24,	 26 NFAT1–NFAT4	 are	 regulated	 by	 intracellular	 Ca2+	 signaling,3,	 4	 whereas	
NFAT5	is	activated	in	response	to	osmotic	stress.24,	27		
	
	
Introduction	
	
	
10	
	
	
	
Figure	2.1.	General	structure	of	Nuclear	Factor	of	Activated	T	cells	(NFAT).	 	NFAT	
consists	of	an	amino‐terminal	regulatory	domain	(also	NFAT	homology	region,	NHR),	a	
DNA‐binding	 domain	 (also	 REL‐homology	 domain,	 RHD),	 and	 a	 carboxy‐terminal	
domain	 (C‐terminal	 domain).	 The	 regulatory	 domain	 contains	 an	 N‐terminal	
transactivation	 domain	 (TAD)	 and	 a	 docking	 site	 for	 casein	 kinase	 1	 (CK1).	 It	 also	
includes	multiple	serine‐rich	motifs	(SRR1,	SP1,	SP2,	SRR2,	SP3	and	KTS)	and	a	nuclear	
localization	sequence	(NLS).	The	RHD	also	contains	points	of	contact	with	Fos	and	Jun.	
(Adapted	from	[4,	24]).		
	
	
	
2.1.2	 Calcium‐calcineurin‐NFAT	signaling	
	
In	the	cytoplasm	of	resting	cells,	NFAT	is	highly	phosphorylated.	The	activation	of	NFAT	
is	 initiated	 when	 cell	 surface	 receptors	 are	 coupled	 to	 Ca2+	 release	 which	 triggers	 a	
process	 that	 leads	 to	 the	 activation	 of	 Ca2+/calmodulin‐dependent	 serine	phosphatase	
calcineurin.2,	 3	 Calcineurin	 is	 essential	 for	 NFAT	 activation	 by	 dephosphorylating	
multiple	 phosphoserines	 in	 the	 regulatory	 domain	 of	 NFAT,	 which	 contributes	 to	 the	
translocation	 of	 NFAT	 to	 the	 nucleus	 where	 it	 mediates	 specific	 transcriptional	
programs.	
NFAT	binds	to	the	promoter	of	a	diversity	of	 inducible	genes	including	those	encoding	
surface	 receptors	 such	 as	 CD40L,	 FASLG	 as	well	 as	 cytokines	 such	 as	 IL‐2,	 IL‐4,	 IL‐5,	
Introduction	
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TNF‐α	and	IFN‐γ,	which	are	essential	for	immune	responses.5,	28‐30	In	addition,	a	number	
of	 evidences	 suggest	 that	 NFAT	 proteins	 are	 involved	 in	 a	 wide	 range	 of	 biological	
responses,16		however,	the	specific	role	of	each	NFAT	family	member	in	mediating	gene	
transcription	during	cell	activation	and	differentiation	is	not	completely	understood.31,	32	
	
	
2.1.3	 Transcriptional	partners	of	NFAT	proteins		
	
Calcineurin‐NFAT	 signaling	 has	 been	 shown	 to	 interact	 with	 many	 other	 signaling	
pathways	 in	 the	 cell	 which	 indicates	 that	 NFAT	 proteins	 cooperate	 with	 different	
transcription	factors.	
Once	inside	the	nucleus,	NFAT	binds	to	the	promoter	of	its	target	genes.	Since	it	can	also	
function	as	dimeric	 transcription	 factor	 (except	 for	NFAT5),33	NFAT	binds	 to	 the	DNA	
either	 with	 another	 NFAT	 molecule	 (homodimer)	 or	 most	 commonly	 with	 other	
transcription	 factors	 (heterodimer).34	 There	 are	 several	 transcription	 factor	 families	
that	 interact	 with	 NFAT,	 including	 activator	 protein	 1	 (AP1),	 forkhead	 box	 P‐family	
proteins	(such	as	FOXP2	and	FOXP3)	and	proteins	of	MAF	and	GATA	families.4	
In	principle,	 this	ability	to	 interact	with	different	transcriptional	partners	allows	many	
signaling	 pathways	 to	 be	 integrated	 leading	 to	 the	 activation	 of	 cell‐type	 specific	
responses	depending	on	which	combination	of	transcription	factors	is	involved.3,	4,	25	
	
2.1.3.1	 AP‐1	
	
Activator	protein	1	(AP1)	transcription	factors	are	the	major	transcriptional	partners	of	
NFAT	 during	 T	 cell	 activation.35	 NFAT‐AP1	 cooperation	 integrates	 several	 signaling	
pathways	 and	 processes,	 namely,	 calcium	 signaling,	 which	 is	 responsible	 for	 the	
activation	 of	 NFAT	 proteins;	 and	 the	 RAS‐MAP	 kinase	 pathway,	 which	 influences	 the	
activation	of	Fos	and	Jun.36‐38	In	the	absence	of	AP1,	NFAT	proteins	have	been	found	to	
activate	 a	 different	 set	 of	 genes	 that	 in	 T	 cells,	 for	 instance,	 leads	 to	 a	 completely	
different	gene	expression	program.39		
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2.1.4	 Inhibition	of	NFAT	activation	
	
2.1.4.1	 Endogenous	inhibitors	
	
In	recent	years,	a	number	of	endogenous	inhibitors	have	been	identified	that	control	the	
activity	 of	 calcineurin	 by	 binding	 to	 calcineurin	 and	 blocking	 its	 phosphatase	 activity.	
These	 inhibitors	 include	 calcineurin‐binding	 protein	 1	 (CABIN1	 or	 CAIN),40	 A‐kinase	
anchor	 protein	 79	 (AKAP79),41,	 42	 the	 members	 of	 the	 calcipressin	 family	 (CSP,	 also	
known	as	modulatory	 calcineurin‐interacting	proteins,	MCIP),	Down	syndrome	critical	
region	 (DSCR)	 proteins	 or	 regulator	 of	 calcineurin	 (RCAN)43	 and	 Calcineurin	
homologous	 protein	 (CHP).44‐46	 As	 specific	 NFAT	 inhibition	 is	 considered	 to	 be	 of	
importance,	 considerable	 effort	 has	 been	 undertaken	 to	 design	 new	 inhibitors	 which	
would	 act	with	higher	 selectivity	 than	 those	 calcineurin	 inhibitors,	 such	 as	VIVIT	 (see	
section	2.1.4.3).47	
		
2.1.4.2	 Immunosuppressive	drugs		
	
The	 interest	 in	 NFAT	 proteins	 increased	 by	 the	 observation	 that	 their	 activation	was	
inhibited	 by	 immunosuppressive	 drugs	 such	 as	 cyclosporin	 A	 (CsA)	 and	 tacrolimus	
(FK506).	 These	 pharmacological	 agents	 are	 widely	 used	 in	 the	 treatment	 of	 patients	
undergoing	transplantation	in	order	to	block	NFAT	activation	in	T	cells.24,	48,	49	CsA	and	
FK506	 inactivate	 the	 canonical	 NFAT	 pathway	 by	 targeting	 the	 endogenous	 cytosolic	
proteins,	 cyclophilin	 (Cyp)	 and	FK506	binding	proteins	 (FKBP)	 (collectively	known	as	
the	 immunophilins),	 respectively.50‐52	 The	 CsA/FK506	 immunophilin	 complexes	 then	
bind	 to	 the	 subunits	 of	 calcineurin	 (CnA	 and	 CnB)	 which	 ultimately	 leads	 to	 the	
disruption	of	calcineurin	activity.53,	54	
A	major	 disadvantage	 of	 these	 agents,	 however,	 is	 that	 by	 inhibiting	 calcineurin	 they	
affect	 the	 entire	 downstream	 signaling	 pathways	 of	 calcineurin	 which	 may	 lead	 to	
undesired	side	effects	and	toxicity.54	Thus,	an	alternative	approach	to	selectively	inhibit	
NFAT	is	crucial.55	
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2.1.4.3	 Specific	peptide	inhibitor	VIVIT	
	
Due	 to	 the	 challenges	 following	 CsA/FK506	 administration,	 there	 was	 an	 attempt	 to	
develop	an	NFAT‐specific	 inhibitor	of	calcineurin	signaling	 that	would	not	affect	other	
calcineurin	substrates.		
Efficient	dephosphorylation	of	NFAT	 in	activated	cells	depends	on	 its	 interaction	with	
calcineurin.	 	 The	 calcineurin	 docking	 site	 in	 the	 regulatory	 domain	 has	 the	 consensus	
sequence	PxIxIT	(where	X	can	be	any	amino	acid),	which	 is	highly	conserved	between	
different	 NFAT	 family	 members.	 Peptides	 binding	 to	 this	 sequence	 are	 able	 to	 block	
NFAT‐calcineurin	interaction	as	well	as	NFAT	activation.	A	high‐affinity	peptide,	VIVIT,	
was	selected	from	a	randomized	peptide	library	and	shown	to	effectively	compete	with	
NFAT	 for	binding	 to	 calcineurin.	Thus,	VIVIT	was	 found	 to	be	a	 suitable	 inhibitor	 that	
specifically	blocks	the	activation	of	NFAT.56‐58	
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2.2	 Hematopoiesis	
	
Hematopoiesis	 represents	 one	 of	 the	 well‐defined	 systems	 of	 adult	 stem	 cell	
development	where	multipotent	hematopoietic	stem	cells	(HSCs)	give	rise	to	a	range	of	
morphologically	 distinct	 mature	 cell	 types,	 all	 characterized	 by	 their	 unique	 gene	
expression	profiles.59‐61	Throughout	adult	 life,	normal	hematopoiesis	takes	place	in	the	
bone	marrow	(BM).	Schofield	demonstrated	 for	 the	 first	 time	 that	 the	stem	cell	 fate	 is	
determined	 by	 the	 surrounding	 microenvironment.62	 At	 present,	 these	 stem	 cell	
microenvironments	are	referred	to	as	stem	cell	niches.63,	64	Consequently,	in	addition	to	
the	cell	 intrinsic	mechanisms,	HSC	behavior	 is	 in	part	 controlled	by	exogenous	 factors	
provided	by	niche	cells.65	This	crosstalk	between	HSCs	and	the	niche	has	been	found	to	
be	 triggered	 by	 a	 variety	 of	 potential	 regulators	 including	 chemokines,	 cytokines	 and	
growth	 factors	 originating	 from	 the	 cells	 itself	 or	 other	 type	 of	 cells,	 as	 well	 as	
interaction	 with	 the	 neighboring	 cells	 and	 the	 extracellular	 matrix	 (ECM),	 notably,	
CXCL12	(SDF‐1)/CXCR4	and	jagged‐1/notch	signaling.66‐68	
Gene	 expression	 induced	 by	 extrinsic	 signals	 works	 together	 with	 the	 intrinsic	 main	
differentiation	 program.65	 A	 large	 repertoire	 of	 molecules	 ranging	 from	 cell	 surface	
receptors	 to	 signal	 transduction	molecules	and	 transcription	 factors	are	 recognized	as	
intrinsic	regulators.	Because	of	their	essential	roles	in	the	development,	expansion	and	
maintenance	 of	 HSCs,	 transcription	 factors	 have	 attracted	 major	 attention	 among	
intrinsic	factors.69	Identification	and	functional	characterization	of	specific	transcription	
factors	will	not	only	advance	our	understanding	of	normal	regulation	of	hematopoiesis	
but	 also	 widen	 our	 prospect	 of	 how	 transcriptional	 regulation	 leads	 to	 diseases	 and	
cancer.	
To	date,	a	number	of	 transcription	 factors	have	been	 identified	which	specify	whether	
HSCs	 remain	 in	 an	 undifferentiated	 state	 or	 differentiate	 along	myeloid,	 lymphoid,	 or	
erythro‐megakaryocytic	lineages.70	For	example,	the	transcription	factors	Runx1	and	Scl	
(Tal1)	were	 found	 to	be	 important	 to	retain	repopulating	activity	and	multipotency	of	
HSC,	 whereas	 transcription	 factors	 like	 Sfpi1	 (Pu.1)	 and	 GATA‐1	 may	 determine	 the	
development	and	lineage	specification	of	HSCs.64,	71	
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Figure	2.2.	A	model	representing	transcriptional	regulation	of	hematopoiesis	and	
hematopoietic	 lineage	 commitment.	 HSC,	 hematopoietic	 stem	 cell;	 LMP,	 lymphoid‐
myeloid	progenitor;	MEP,	megakaryocyte‐erythroid	progenitor;	CMP,	common	myeloid	
progenitor;	CLP,	common	lymphoid	progenitor.72‐75	
	
	
2.2.1	 NFAT	in	hematopoiesis	
	
The	regulated	expression	of	lineage‐specific	genes	during	hematopoiesis	is	essential	for	
the	 proliferation	 and	 differentiation	 of	 hematopoietic	 cells.76	 A	 wide	 variety	 of	
transcription	factors	(as	mentioned	above)	has	been	identified	as	being	critical	for	HSC	
regulation.	Boer	et	al.	suggested	that	NFAT	is	the	regulator	of	various	cytokines,	which	
are	 involved	 in	 the	 regulation	 of	 hematopoietic	 cells,	 e.g.	 IL‐4,	 IL‐3,	 IL‐5,	 IL‐13	 and	
granulocyte‐macrophage	colony	stimulating	factor	(GM‐CSF).77	
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In	 a	 study	of	Kiani	 et	 al,	 the	 gene	 expression	pattern	of	 each	NFAT	 family	member	 in	
CD34+	 hematopoietic	 stem	 cells	 and	 during	 their	 lineage	 commitment	 to	 various	
hematologic	 cell	 types	 (i.e.,	 eosinophil,	 neutrophil,	 erythroid,	 or	 megakaryocytic	
lineages)	was	 established.	 Subsequent	 results	 showed	 that	NFAT	expression	 follows	 a	
lineage‐	 and	 partly	 also	 family	 member‐specific	 pattern	 during	 myeloid	
differentiation,78,	79	showing	that	NFATc2	protein	is	not	expressed	in	mature	neutrophils	
and	 monocytes.	 Eosinophils	 express	 NFATc1,	 c2	 and	 c3,80‐82	 whereas	 mature	
megakaryocytes	only	 strongly	 express	NFATc2	and	NFATc4.79	 	 In	 contrast,	monocytes	
are	found	to	be	devoid	of	NFAT	expression.74		
Furthermore,	it	is	known	from	recent	studies	that	while	the	calcineurin/NFAT	signaling	
pathway	is	crucial	for	many	aspects	of	vertebrate	development,	such	as	the	regulation	of	
lymphocyte	development,	 it	 is	not	essential	 for	the	development	of	myeloid	 lineages.83	
In	a	study	by	Bauer	et	al,	in	which	the	role	of	NFATc2	in	hematopoiesis	was	investigated,	
it	has	been	shown	that	the	differentiation	potential	of	HSCs	is	preserved	in	the	absence	
of	NFATc2.	Furthermore,	it	was	shown	in	the	same	study	that	NFAT	activation	was	not	
required	for	megakaryocytic	differentiation	in	ex	vivo cultures	of	normal	HSCs.84	
Since	the	expression	of	selected	NFAT	family	members	(including	NFATc2)	 is	 found	to	
be	maintained	or	even	upregulated	during	megakaryopoiesis,	a	major	part	of	this	study	
was	assigned	to	study	the	role	of	NFAT	in	megakaryocytes.	
	
	
2.2.2	 HSC	 transplantation:	 A	 tool	 to	 investigate	 the	 regulation	 of	
hematopoiesis					
	
Hematopoiesis	 occurs	 in	 the	 BM	 and	 in	 close	 contact	with	 BM	 stroma	 cells.63,	 85,	 86	 A	
number	 of	 interactions	 and	 signaling	 pathways	 maintain	 the	 intimate	 association	 of	
HSCs	 and	 marrow	 stroma	 cells.	 An	 increasing	 number	 of	 studies	 is	 focused	 on	 the	
influence	of	the	niche	on	viability,	proliferation	and	differentiation	of	HSCs.	Yet,	there	is	
only	 little	 evidence	 that	 HSCs	 participate	 in	 the	 development	 of	 the	 niche.87	 Because	
HSCs	are	pluripotent	they	have	the	capability	of	self‐renewal	as	well	as	giving	rise	to	all	
hematopoietic	lineages.88	
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Hematopoietic	 stem	 cell	 transplantation	 (HSCT)	 is	 a	 medical	 approach	 used	 in	
conjugation	 with	 high	 dose	 chemotherapy	 and/or	 irradiation	 for	 the	 treatment	 of	
aberrant	hematopoiesis	resulting	from	intrinsic	marrow	defects.89,	90	 	This	may	emerge	
from	 a	 lack	 or	 malfunction	 of	 either	 extrinsic	 or	 intrinsic	 factors	 involved	 in	
hematopoiesis	(for	details	see	section	2.2).	Therefore,	HSC	transplantation	experiments	
are	 an	 adequate	 approach	 to	 fully	 explore	HSC	 functions	 and	 interactions	 in	vivo.91,	 92	
The	 standard	approach	 in	both	patients	and	experimental	 animals	 is	 to	 inject	 isolated	
HSCs	 intravenously.93	 In	 this	process,	HSCs	 find	their	way	to	the	host's	BM	niche	via	a	
mechanism	 referred	 to	 as	 'homing'.94	 Transplantation	 chimera	 studies	 in	 transgenic	
models,	in	which	either	the	host	or	the	donor	harbor	a	genetic	defect,	may	facilitate	the	
characterization	 of	 the	 differential	 contribution	 of	 HSCs	 and	 stroma	 cells	 to	 a	 given	
phenotype.84	
	
	
	
	
	
	
	
	
2.3	 Mouse	model	of	NFATc2	deficiency	
	
Recent	 investigations	on	NFAT‐deficient	mice	suggest	that	the	 involvement	of	NFAT	in	
the	regulation	of	cellular	physiology	such	as	proliferation,	cell	growth	and	apoptosis	 is	
much	broader	than	previously	thought.95‐97	Although,	NFAT	proteins	are	considered	to	
have	 redundant	 functions	 in	 the	 cell,	 recent	 studies	 on	 mice	 lacking	 NFAT	 family	
members	suggest	that	they	play	distinct	roles	in	the	regulation	of	cell	activities.31,	32,	98	
NFATc2‐/‐	mice	display	a	 lymphocyte	hyperproliferative	phenotype	with	an	increase	in	
the	 size	 of	 peripheral	 lymphoid	 organs,	 typically	 accompanied	 by	 a	 consistently	
enhanced	T	helper	type	2	immune	response,	a	reduction	in	programmed	cell	death	and	
an	 increased	 cell	 cycle	 rate	 of	 lymphocytes.	 Also,	 they	 exhibit	 distinct	 defects	 in	
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controlling	the	promoter	of	cytokines	and	cell	surface	receptors,	including	CD25,	CD40L	
and	FASLG.30,	 99‐102	However,	NFATc2‐/‐	mice	develop	normally	and	do	not	exhibit	 any	
deficiencies	in	their	behavioral	phenotype.31,	103	
An	 increasing	 number	 of	 evidence	 suggests	 that	 NFAT	 transcription	 factors	 are	
associated	 with	 gene	 expression	 in	 a	 variety	 of	 cell	 types.	 In	 addition	 to	 lymphocyte	
hyperproliferation,	the	absence	of	NFATc2	 in	vivo	 leads	to	alterations	in	the	regulation	
of	cell	cycle,	most	 likely	due	to	an	 increase	 in	the	expression	of	cyclins.31,	 97	Moreover,	
lack	 of	 NFATc2	 causes	 an	 uncontrolled	 growth	 of	 cartilage	 and	 skeletal	 muscle	 cells	
implying	a	suppressor	role	for	NFATc2	in	these	cells.18,	104	Others	also	demonstrated	that	
NFATc2	deficiency	 leads	 to	 articular	 cartilage	degradation	probably	due	 to	 the	 loss	of	
type‐II	collagen	(collagen‐2)	in	articular	chondrocytes.105		
In	 our	 previous	 study	 on	 aged	 NFATc2‐deficient	mice	 (>12	months	 old)	we	 reported	
that	these	mice	develop	anemia,	thrombocytopenia,	and	lymphocytosis.	Lack	of	NFATc2	
in	these	mice	leads	to	BM	hypoplasia	with	a	remarkable	loss	of	blood	cells	of	erythroid,	
granulocytic,	 and	megakaryocytic	 lineages,	 while	 the	 differentiation	 potential	 of	 their	
progenitors	remains	intact.	Moreover,	as	reflected	by	the	presence	of	bone	trabeculae	as	
well	as	reticular	fibers	in	the	marrow	cavity,	these	mice	display	osteomyelosclerosis	(in	
some	cases	osteomyelofibrosis	or	myelofibrosis).	Also,	 the	 spleen	of	NFATc2‐/‐	mice	 is	
enlarged	 and	 harbors	 extramedullary	 hematopoiesis.	 Consequently,	 mice	 with	 a	
deficiency	in	NFATc2	are	found	to	be	an	appropriate	model	to	study	the	role	of	NFATc2	
in	hematopoiesis	and	bone	remodeling	in	adult	organisms.84,	106	
	
	
	
	
	
	
2.4	 Megakaryocytes	and	megakaryopoiesis		
	
Megakaryocytes	 (MKs),	 a	 small	 population	 (<0.5%)	 of	 BM	 cells,	 arise	 from	
hematopoietic	 stem	cells	 and	are	well‐known	 to	 fulfil	 the	major	 function	of	producing	
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blood	 platelets.	 They	 therefore	 represent	 an	 integral	 part	 of	 primary	 hemostasis,	
thrombosis	and	wound	healing.107,	108	MKs	have	been	characterized	as	the	largest	cell	of	
the	BM	with	a	multilobed	and	polyploid	nucleus.		
MKs	 undergo	 a	 differentiation	 process,	 known	 as	 "megakaryopoiesis",	 in	 which	
multipotent	HSCs	 convert	 to	 committed	megakaryocyte‐erythroid	 precursors	 (MEP	 in	
figure	 2.2),75	 colony	 forming	 unit	 megakaryocytes	 (CFU‐MK)	 and	 immature	 MKs	 or	
megakaryoblasts,	 respectively.	 CFU‐MK	 are	 considered	 the	 first	 stage	 of	
megakaryopoiesis	 that	 shows	 distinct	 megakaryocyte‐lineage	 surface	 markers.109	
Further	 maturation	 is	 followed	 by	 cell	 enlargement,	 membrane	 demarcation	 and	
endomitosis	which	results	in	polyploid	MKs	that	no	longer	proliferate.	Polyploidization	
is	a	unique	hallmark	of	MKs	as	a	prerequisite	 for	proplatelet	 formation	and	ultimately	
platelet	production.110‐112	Among	a	number	of	 cytokines	which	mediate	 the	process	of	
megakaryopoiesis,	 thrombopoietin	 (TPO)	 has	 been	 demonstrated	 as	 the	 major	
physiological	factor	for	megakaryocyte	lineage	development.113‐118	In	spite	of	TPO	which	
is	 essential	 for	 the	 whole	 process	 of	 megakaryopoiesis,	 other	 cytokines	 including	
interleukin‐3	(IL‐3),	granulocyte	colony‐stimulating	factor	(G‐CSF)	and	GM‐CSF	act	only	
on	early	stages	of	megakaryopoiesis.119,	120	
Increasing	 evidence	 suggests	 that	MKs	may	 serve	 an	 additional,	 cell‐intrinsic	 function	
that	extends	beyond	their	role	as	platelet	producers.	 In	addition	to	their	main	location	
(BM),	 MKs	 can	 also	 be	 found	 in	 spleen,	 lung,	 liver,	 cord	 blood	 (CB)	 and	 mobilized	
peripheral	 blood	 (MPB)	 under	 certain	 conditions	 of	 stress,	 inflammation	 and	 organ	
damage.121‐124	MKs	dysfunction	has	been	implicated	in	the	induction	of	several	myeloid	
disorders	such	as	myelodysplastic	syndrome	(MDS)	and	chronic	myelogenous	leukemia	
in	 which	 the	 number	 of	 small	 hypolobulated	 MKs	 is	 increased	 in	 the	 BM.	 Excess	
production	of	cytokines	and	growth	factors	(namely	TGF‐ß)	by	MKs	has	been	shown	to	
contribute	 to	 diseases	 such	 as	 idiopathic	 myelofibrosis	 (IMF).125	 Therefore,	
understanding	the	mechanisms	regulating	the	physiology	and	pathophysiology	aspects	
of	MKs	is	of	importance.	
	MKs	are	also	known	to	express	a	number	of	genes	with	established	immunomodulatory	
properties	 (e.g.	 TNF‐α,	 TRAIL,	 CD154,	 FASLG),	 which	 they	 pass	 on	 to	 platelets.126,	 127		
Whether	expression	of	these	membrane	proteins	is	of	intrinsic	biological	significance	for	
these	cells,	however,	is	still	under	investigation.		
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2.4.1	 Transcriptional	regulation	of	megakaryopoiesis	
	
Development	and	differentiation	of	MKs	and	production	of	platelets	–megakaryopoiesis	
and	 thrombopoiesis,	 respectively–	 are	 controlled	 by	 molecular	 pathways.	 Like	 other	
blood	cells,	MKs	develop	from	a	common	BM	hematopoietic	stem	cell.	A	wide	variety	of	
growth	factors	and	cytokines	were	identified	to	regulate	megakaryopoiesis.	In	addition,	
a	number	of	transcription	factors	are	enriched	in	MKs.128	The	Ets‐gene	family	including	
Fli‐1	 and	Ets‐1	 has	 been	 reported	 as	 a	 positive	 regulator	 of	megakaryopoiesis.129	 The	
activation	 of	 Fli‐1	 results	 in	 increased	 expression	 of	 megakaryocyte‐specific	 genes,	
namely	genes	related	to	megakaryocytic	phenotype	markers	such	as	CD41	and	CD61.112		
Fli‐1	deficiency	in	mice	results	in	impaired	megakaryopoiesis	and	thrombocytopenia.128,	
130	 Fli‐1	 is	 involved	 in	 the	 interaction	 of	 GATA‐1	 and	 friend	 of	 GATA‐1	 (FOG‐1),	 two	
transcription	 factors	which	 are	 important	 for	many	 stages	 of	megakaryopoiesis.131‐133	
GATA‐1	 knockout	 mice	 harbor	 thrombocytopenia	 and	 a	 delay	 in	 megakaryocytic	
development.134	In	other	studies,	GATA‐1	has	been	introduced	as	a	negative	regulator	of	
cell	 proliferation	 in	 early	 megakaryopoiesis.135,	 136	 Mice	 lacking	 FOG‐1	 also	 show	 an	
absence	of	MK	progenitors.137	Humans	with	GATA‐1	mutations	that	prevent	interaction	
with	its	cofactor	FOG‐1	are	severely	thrombocytopenic.138	TEL,	also	belonging	to	the	Ets	
family	of	transcription	factors,	is	a	regulator	of	hematopoiesis.	Because	it	can	act	as	an	
inhibitor	of	Fli‐1,	its	absence	leads	to	impairment	of	MK	maturation.139	The	transcription	
factor	nuclear	factor‐erythroid	2	(NF‐E2)	has	been	widely	studied	and	shown	to	regulate	
the	expression	of	genes	mediating	the	terminal	stage	of	megakaryopoiesis	as	well	as	of	
thrombopoiesis	 including	 ß‐tubulin	 and	 thromboxane	 synthase.	 NF‐E2	 knockout	mice	
exhibit	profound	thrombocytopenia	due	to	dysfunctional	MKs	(reviewed	in	Schulze	and	
Shivdazani	2005).128,	140	Runt‐related	transcription	factor	1	(RUNX‐1)	also	functions	as	a	
regulator	of	the	later	stages	of	megakaryopoiesis	as	its	absence	results	in	the	reduction	
of	 polyploidization	 and	 platelet	 number,	 however,	 RUNX‐1	 target	 genes	 in	 MKs	 still	
remain	to	be	identified.141	
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2.4.2	 Transcriptional	regulation	by	NFAT	in	megakaryocytes	
	
As	 described	 in	 section	 2.3,	 aged	 mice	 lacking	 NFATc2	 harbor	 thrombocytopenia.	 In	
addition,	MKs	 have	 been	 implicated	 to	 have	 a	 primary	 role	 in	myelofibrosis,	which	 is	
observed	in	aged	NFATc2‐/‐	mice.		The	investigation	by	Kiani	et	al.	demonstrated	for	the	
first	 time	 that	 the	 expression	 of	 NFAT	 family	 member	 c2	 is	 maintained	 or	 even	
upregulated	 during	 megakaryopoiesis.79	 Subsequent	 studies	 suggested	 that	
calcineurin/NFAT	 activation	 is	 dispensable	 for	 effective	 megakaryopoiesis,	 but	
contributes	to	MK	function	by	regulating	the	expression	of	a	number	of	megakaryocytic	
genes	e.g.	FASLG,	RCAN1	and	CD40LG.79,	126,	142,	143	FASLG,	a	known	NFATc2	target	in	T	
lymphocytes,	 was	 established	 as	 the	 first	 NFATc2	 target	 gene	 in	 MKs	 at	 the	 mRNA	
level.79,	143	However,	the	biological	relevance	of	these	findings	remained	unknown.	
	
2.4.2.1	 Fas	Ligand	
	
FASLG,	 a	 proapoptotic	 member	 of	 the	 tumor	 necrosis	 factor	 superfamily,	 has	 been	
established	as	an	NFAT	target	in	T	cells.28,	144,	145	The	membrane‐bound	FASLG	is	cleaved	
by	 an	 external	 matrix	 metalloproteinase	 (namely,	 MMP‐7)	 and	 generates	 the	 soluble	
version	 (sFASLG),	 which	 is	 found	 to	 be	 less	 efficient	 in	 inducing	 apoptosis	 in	 target	
cells.146	Expression	of	functional	FASLG	by	activated	T	cells	and	natural	killer	(NK)	cells	
plays	 a	 key	 role	 in	 eliminating	 T	 cell	 populations	 following	 antigenic	 stimulation	 and	
clonal	 proliferation.147,	 148	 On	 the	 other	 hand,	 FASLG	 expression	 by	 cells	 of	 immune‐
privileged	 tissues,	 such	as	 testis	and	 the	eye,	prevents	 the	 infiltration	of	 inflammatory	
leucocytes.149	
	
2.4.2.2	 Fas/Fas	Ligand‐induced	apoptosis	
	
	FASLG	ligation	leads	to	trimerization	of	its	receptor	(Fas)	on	target	cells,	which	results	
in	 the	 activation	 of	 a	 death	 signaling	 cascade	 and	 the	 induction	 of	 apoptosis	 in	 Fas‐
bearing	 cells.150	 	 Fas	 is	 constitutively	 expressed	 in	 most	 cell	 types	 (notably	 on	
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hematopoietic	 cells	 and	 lymphocytes),151	 but	 the	 expression	 of	 its	 ligand	 (FALSG)	 is	
more	restricted.		
Apoptosis,	 an	 evolutionary	 conserved	 biological	 process,	 also	 known	 as	 type	 I	
programmed	cell	death,	plays	a	critical	role	in	physiological	and	pathological	processes.	
Apoptosis	is	characterized	by	a	diverse	range	of	structural	alterations	in	cells,	including	
blebbing	 of	 plasma	membrane,	 nucleus	 condensation,	 DNA	 fragmentation,	 cleavage	 of	
some	cellular	proteins,	cytochrome	c	release	from	mitochondria	and	decreased	caspase	
activation.152‐154	 Disturbance	 of	 apoptosis	 pathways	 (e.g.,	 in	 death	 receptor	 and	
mitochondrial	 pathways)	may	 result	 in	 the	 pathogenesis	 of	 different	 diseases	 such	 as	
cancer.155,	156	
	
	
	
	
2.5	 RNA	sequencing	
	
Gene	expression	analysis	 is	a	general	method	by	which	mRNA	 levels	of	a	certain	gene	
are	quantified.	Although	microarrays	are	nowadays	routinely	used	for	gene	expression	
analysis	 purposes,	 the	 next‐generation	 sequencing	 (NGS)	 methods	 are	 rapidly	
progressing.	 NGS	 technologies	 that	 measure	 genome‐wide	 transcription	 levels	 are	
termed	 as	mRNA	 sequencing	 (RNA‐Seq)	which	 have	 clear	 advantages	 over	 previously	
applied	 gene	 expression	 technologies.157‐160	 In	 fact,	 RNA‐Seq	 provides	 much	 greater	
sensitivity	 and	 a	 more	 accurate	 estimation	 of	 absolute	 expression	 levels	 than	
microarrays	 and	 allows	 studying	 the	 events	 which	 are	 beyond	 the	 reach	 of	
microarrays.161‐163	
In	 principle,	 isolated	 total	 RNA	 is	 copied	 to	 complementary	 DNA	 (cDNA)	 and	 cut	 at	
random	 positions.	 Fragments	 with	 a	 certain	 size	 are	 selected	 for	 amplification	 with	
polymerase	chain	reaction	(PCR).	Next,	the	amplified	cDNA	is	sequenced	by	NGS	method	
which	 generated	 tens	 of	 millions	 of	 digital	 signals	 (short	 sequence	 reads)	 from	 the	
transcripts	of	the	genes	of	interest	which	are	then	aligned	to	a	reference	genome.	These	
digital	gene	counts	even	from	a	transcript	with	low	or	moderate	abundance	are	highly	
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reproducible	and	have	the	potential	to	be	used	for	gene	expression	analysis.159,	162,	164	In	
order	 to	 process	 these	 intensive	 computational	 steps,	 however,	 powerful	 servers	 and	
bioinformatics	skills	are	required.160	
Although	 novel	 NGS	 methods	 in	 terms	 of	 procedure,	 technique	 and	 accuracy	 vary	
considerably	 in	comparison	to	microarray	 technologies,	 the	principles	of	experimental	
design	are	similar.159	One	approach	that	ensures	a	successful	gene	expression	study	 is	
the	 application	of	 replicates.	 	 In	particular,	 biological	 replicates	 (“true”	 replicates)	 are	
desirable	 as	 they	 indicate	 the	 variation	 among	 biological	 samples.	 When	 the	 same	
biological	 sample	 is	measured	 repeatedly	 (normally	 ≥	 three	 times),	 the	 replicates	 are	
termed	 “technical”	 replicates.	 Hence,	 a	 careful	 design	 is	 essential	 to	 distinguish	
biological	 variation	 from	 technical	 variation	 and	 to	 draw	a	more	 confident	 conclusion	
from	experiments.165	
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3	 Aim	of	the	study	
	
The	aim	of	the	present	study	was	to	characterize	the	role	of	NFAT	transcription	factors	
in	hematopoiesis	with	a	focus	on	megakaryocytes.	
	
1‐	NFATc2	has	been	shown	to	be	expressed	in	CD34+	hematopoietic	stem	cells.	Previous	
studies	 on	 mice	 lacking	 NFATc2	 demonstrated	 hematological	 and	 osteological	
abnormalities.	The	role	of	NFATc2	in	hematopoiesis	and	the	respective	contribution	of	
hematopoietic	 and	 stroma	 cells	 to	 the	 phenotype	 of	 NFATc2‐deficient	mice,	 however,	
remained	unclear.	Therefore,	transplantation	experiments	–in	which	purified	HSCs	from	
WT	mice	were	transplanted	to	NFATc2‐deficient	mice	and	vice	versa–	were	performed	
to	address	this	question.		
	
2‐	Mice	 lacking	NFATc2	exhibit	thrombocytopenia	and	myelofibrosis.	Both	phenotypes	
potentially	 are	 caused	 by	 megakaryocyte	 dysfunction.	 Moreover,	 NFATc2	 has	 been	
shown	 to	 be	 upregulated	 during	 megakaryocyte	 differentiation,	 though	
megakaryopoiesis	 proved	 to	 occur	 normally	 in	 the	 absence	 of	NFATc2.	 Therefore,	we	
sought	 to	 investigate	 whether	 the	 calcineurin/NFAT	 pathway	 is	 involved	 in	 the	
regulation	of	gene	expression	in	mature	megakaryocytes.	
	
a)	 Fas	 Ligand,	 a	 proapoptotic	 member	 of	 the	 TNF‐superfamily,	 has	 been	 previously	
identified	by	our	group	as	an	NFATc2	 transcriptional	 target	 in	megakaryocytes	on	 the	
mRNA	 level.	 In	 this	 study	 we	 aimed	 to	 extend	 these	 findings	 and,	 in	 particular,	 to	
advance	them	to	a	functional	level.	
	
b)	 In	order	 to	 further	explore	 the	potential	 function	of	 the	NFAT	signaling	pathway	 in	
mature	megakaryocytes,	the	global	profile	of	NFATc2‐regulated	target	genes	in	this	cell	
type	was	analyzed.		
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4	 Materials	and	methods	
4.1	 Materials	
4.1.1	 Reagents,	stimulators,	inhibitors	and	growth	factors	
Name	 Company/location	
Alizarin	red	 Sigma,	St.	Louis,	MO,	USA	
L‐Ascorbate	 Sigma,	St.	Louis,	MO,	USA	
ß‐Glycerol	phosphate	 Sigma,	St.	Louis,	MO,	USA	
Bovine	serum	albumin	(BSA)	 Sigma,	St.	Louis,	MO,	USA	
Cellgro,	serum‐free	medium	 CellGenix,		Freiburg,		Germany	
Cetylpyridinium	chloride	 Sigma,	St.	Louis,	MO,	USA	
Collagen	solution	 StemCell	Technologies,	Vancouver,	
Canada	
Collagenase		type	1	 Worthington,		NJ,	USA	
Cyclosporin	(CsA)	 Sigma,	Deisenhofen,	Germany	
DAPI	(4',6‐diamidino‐2‐phenylindole)	 Sigma,	St.	Louis,	MO,	USA	
DMEM	 GIBCO,	Darmstadt,	Germany	
Fetal	calf	serum	(FCS)	 GIBCO,	Darmstadt,	Germany	
Hybond‐ECL	Nitrocellulose	 Amersham	Pharmacia	Biotech,	Little	
Chalfont,	UK	
Interleukin‐3	(IL‐3)	 Strathmann	Biotec	AG,	Hamburg,	
Germany	
Interleukin‐6	(IL‐6)	 Strathmann	Biotec	AG,	Hamburg,	
Germany	
Ionomycin	 Calbiochem/Merck	Biosciences,	Bad	
Soden,	Germany	
Matrix	metalloproteinase	inhibitor	 Sigma,	Deisenhofen,	Germany	
Merckoglas	 Merck	KGaA,	Darmstadt,	Germany	
Megacult‐C	serum	free	medium		(M4960)	 StemCell	Technologies,	Vancouver,	
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Canada	
Methylcellulose‐based	semisolid	medium	
(MethoCult	GF	M3434)		
StemCell	Technologies,	Vancouver,	
Canada	
Nonidet	P‐	40	 Roche,	Mannheim,	Germany	
Osteosoft	 Merck,	Darmstadt,	Germany	
Paraformaldehyde	(PFA)	 Merck,	Darmstadt,	Germany	
Penicillin/Streptomycin	(pen/strep)	 PAA	Laboratories,	Pasching,	Austria	
Phorbol	12‐myristate	13‐acetate	(PMA)	 Sigma,	Deisenhofen,	Germany	
Phosphate	buffered	saline	(PBS)	powder	 GIBCO,	Darmstadt,	Germany	
Phosphate	buffered	saline	(PBS)	solution	 PAA	laboratories,	Pasching,	Austria	
ProLong®		gold	anti‐fade	 Life	technologies	GmbH,		Darmstadt,	
Germany	
Roti‐Load1	4xloading	buffer	 Roth,	Karlsruhe,	Germany	
RPMI‐1640	 Invitrogen	GmbH,		Karlsruhe,		
Germany	
Sodium	azide	(NaN3)	 Sigma,	St.	Louis,	MO,	USA	
Thrombopoietin	(TPO)	 Strathmann	Biotec	AG,	Hamburg,	
Germany	
Trizol		 Invitrogen,	Darmstadt,	Germany	
Tween20	 SERVA,	Heidelberg,	Germany	
	
	
4.1.2	 Antibodies	
Name	 Isotype	 Company/location	
Anti‐human	 	 	
Fas	(clone	ZB4)	 mouse	IgG1		
(antagonist)	
Millipore	,Temecula,	CA,	USA	
Fas	(clone	CH11)	 mouse	(agonist)	 Millipore	,Temecula,	CA,	USA	
CD178	(clone	NOK‐1)							 Purified	mouse	IgG1	 BDBiosciences	,Palo	Alto,	CA,	USA	
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CD178	(clone	G247‐4)	 Mouse	IgG1	 BDBiosciences	,Palo	Alto,	CA,	USA	
ß‐actin	(clone	AC‐40)													 Mouse	IgG2a	 Sigma,	Deisenhofen,	Germany	
CD178‐	biotin	 Mouse	IgG1	 BDBiosciences	,Palo	Alto,	CA,	USA	
CD61‐FITC	 Mouse	IgG1	 Beckman	Coulter,	Immunotech	,	
CA,	USA	
Anti‐mouse	
CD117(cKit)	‐APC	 Rat	IgG2b,k	 eBiosciences,	San	Diego,	CA,	USA	
Ly‐6A/E	(Sca‐1)	‐PE	 Rat	IgG2b,k	 eBiosciences,	San	Diego,	CA,	USA	
Isotype	controls	
IgG‐	FITC	 Mouse	IgG2b,k	 eBiosciences,	San	Diego,	CA,	USA	
IgG‐PE	 Mouse	IgG2a	 Beckman	Coulter	,	Immunotech	,	
CA,	USA	
IgG‐	APC	 mouse	IgG1,k	 BDPharmingen,	PaloAlto,	CA,	USA	
IgG‐FITC	 Rat	IgG2a,k	 BDPharmingen,	PaloAlto,	CA,	USA	
IgG‐PE	 Rat	IgG2a,k	 BDPharmingen,	PaloAlto,	CA,	USA	
Secondary	antibodies	/	Fluorophores	
Allophycocyanin	(APC)	 	 BDBiosciences	,Palo	Alto,	CA,	USA	
Horseradish	 peroxidase	
(HRP)‐conjugated	IgG	
anti‐mouse		 Dako	,Hamburg,	Germany	
Cy‐3	conjugated	IgG	 anti‐mouse	 Sigma	,Deisenhofen,	Germany	
Streptavidin	 	 DAKO,	Glostrup,	Denmark	
	
	
4.1.3	 KITs	
Kit	name	 contents	 Company/location	
CD34		MicroBead		  CD34	MicroBeads,	human	
 	FcR	blocking	reagent	
Miltenyi	Biotec,	Bergisch	
Gladbach,	Germany	
Apoptosis	detection		  annexin	V‐APC	
 7‐AAD	
BD	Biosciences	,Palo	
Alto,	CA,	USA	
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CellTraceTM	CFSE	cell	
proliferation		
 CFSE	(6‐carboxyfluorescein	
succinimidyl	ester)	
 DMSO	(Dimethyl	sulfoxide)	
Molecular	probes,	
Eugene,	OR,	USA	
Cell	proliferation	(MTT)	  MTT;	 3‐(4,5‐Dimethylthiazol‐2‐
yl)‐2,5‐diphenyltetrazolium	
bromide)	
Roche	 Applied	 Science,	
Mannheim,	Germany	
Enhanced	
chemiluminescence	
detection	 (ECL	 and	 ECL	
plus)	
	 Amersham	GE	
Healthcare,	
Buckinhamshire,	UK	
Lineage	 cell	 depletion	
(mouse)	
 biotinylated	 	 lineage	Ab	cocktail	
(CD5,	 CD45R,	 CD11b,	 Gr‐1,	 Ter‐
119)		
 anti‐biotin	MicroBeads	
Miltenyi	 Biotec,	 Bergisch	
Gladbach,	Germany	
	µMACS	mRNA	isolation	 	 Miltenyi	 Biotec,	 Bergisch	
Gladbach,	Germany	
	
4.1.4	 Primers	
Primer	pairs	for	DSCR1	 	
Forward:	CCCGACAAACAGTTCCTCAT	 Reverse:	CACTGGGAGTGGTGTCTGTC	
	
	
	
4.2	 Equipment	
4.2.1	 Instruments	
Name	 Company/location	
AB	7500	Real‐time	PCR	system	 Applied	Biosystems,	Foster	city,	CA,	USA	
Bioanalyzer	2100	 Agilent	Technologies,	Santa	Clara,	CA,	USA	
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FACScalibur	(fluorescence	activated	cell	
sorting)	
BD	Biosciences,	San	Jose,	CA,	USA	
FACS	Aria	II	 BD	Biosciences,	San	Jose,	CA,	USA	
Hoefer	SE	Migthy	Small	Mini	vertical	unit	
(Electrophoresis	device)	
Hoefer,	San	Francisco,	CA,	USA	
Hoefer	TE	22	Series	Transpher	unit	
(Western	Blotting	device)	
Hoefer,	San	Francisco,	CA,	USA	
Illumina	HiSeq	2000	 Illumina	Inc,	San	Diego,	CA,	USA	
IMAC	S30	Video	CCD	camera	 Nikon	GmbH,Düsseldorf,	Germany	
NanoDrop	2000	spectrophotometer	 Thermo	Fisher	scientific	Inc.,	Wilmington,	
DE,	USA	
Nikon	digital	sight	camera	DS‐5M	 Nikon	GmbH,	Düsseldorf,	Germany	
Nikon	Eclipse	E600	light	microscope	 Nikon	GmbH,	Düsseldorf,	Germany	
Nikon	Eclipse	E800	fluorescence	
microscope	
Nikon	GmbH,	Düsseldorf,	Germany	
Sysmex	hematology	analyzer	 Sysmex,	Norderstedt,	Germany	
	
	
4.2.2	 Software	
Name	 Company/location	
Cellquest		 BD	Biosciences,	San	Jose,	CA,	USA	
FACSDiva	(version	6.1.3)	 BD	Biosciences,	San	Jose,	CA,	USA	
GraphPad	Prism	(version	4.03)	 GraphPad	Software,	La	Jolla,	CA,	USA	
Isis software	(version	5.2.20)	 Metasystems	GmbH,	Altlussheim,	Germany
NIS‐Elements	D	Imaging	(version	2.30)	 Nikon	GmbH,	Düsseldorf,	Germany	
'R'	software	environment	and	
programming	language	
The	R	Foundation	for	Statistical	
Computing,	Vienna,	Austria	
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4.3	 Cell	culture	
Cell lines 
The	 Meg‐01,	 CMK	 and	 Jurkat	 cell	 lines	 were	 obtained	 from	 the	 German	 collection	 of	
microorganisms	 and	 cell	 cultures	 (DSMZ,	 Braunschweig,	 Germany).	 All	 cell	 lines	were	
cultured	in	RPMI‐1640	supplemented	with	1%	penicillin/streptomycin	(pen/strep)	and	
either	15%	(CMK)	or	10%	(Meg‐01	and	Jurkat)	FCS.	
	
Isolation and differentiation of human CD34+ cells into megakaryocytic cells 
CD34+	 cells	 were	 isolated	 by	 immunomagnetic	 selection	 from	 peripheral	 blood	 of	
granulocyte	 colony‐stimulating	 factor‐(G‐CSF‐)	 mobilized	 healthy	 stem	 cell	 donors,	
using	CD34	MicroBead	kit,	according	to	instructions	provided	by	the	manufacturer.	The	
purities	of	the	resulting	CD34+	populations	were	assessed	by	fluorescence‐activated	cell	
sorting	 (FACS)	 and	 routinely	 exceeded	 95%.	 The	 study	 was	 approved	 by	 the	
Institutional	 Review	 Board	 of	 the	 Medical	 Faculty	 of	 the	 Dresden	 University	 of	
Technology,	and	informed	consent	was	obtained	from	the	donors.		
Ex	vivo	differentiation	of	CD34+	cells	into	MKs	was	performed	as	follows.	Purified	CD34+	
cells	were	seeded	at	0.4	x	106/ml	in	Cellgro	Stem	Cell	Growth	Medium	and	cultured	for	
10‐12	days	in	the	presence	of	100	ng/ml	TPO	(with	a	change	of	medium	every	4	days)	to	
induce	 megakaryocytic	 differentiation.	 The	 differentiation	 efficacy	 was	 analyzed	 for	
each	experiment	by	FACS	analysis	of	the	lineage‐specific	cell	surface	marker	CD61.	
	
Retroviral transduction 
The	generation	of	stably	transduced	CMK	cell	lines	either	overexpressing	NFATc2‐IRES	
(internal	ribosome	entry	site)‐EGFP	(enhanced	green	fluorescent	protein),	or	expressing	
VIVIT‐GFP	or	IRES‐EGFP	(control)	as	well	as	the	corresponding	retroviral	vectors	have	
been	described.	79,	143	The	transduced	cells	were	sorted	for	EGFP	expression,	and	EGFP	
expression	was	confirmed	by	FACS	at	regular	intervals.	
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Stimulation of human megakaryocytic cells 
Culture‐derived	MKs	or	CMK	cells	were	seeded	at	1	x	106/ml	 in	Cellgro	or	RPMI‐1640	
medium	and	were	either	left	unstimulated	or	stimulated	at	37°C	for	the	indicated	time	
points	 with	 ionomycin	 (1µM).	Where	 indicated,	 a	 30‐minutes	 pretreatment	 with	 CsA	
(1µM)	prior	to	agonist	stimulation	was	used	to	block	calcineurin	activation.	At	the	end	of	
the	stimulation,	the	cells	were	harvested	and	directly	used	for	further	analysis.	
	
Ex vivo differentiation of murine megakaryocytes 
Bone	marrow	was	flushed	from	both	femora	and	tibiae.	Bone	marrow	cell	suspensions	
were	passed	through	a	70	µm	nylon	mesh	cell	strainer	to	obtain	single	cell	suspensions.	
Afterwards,	the	cells	were	incubated	with	a	biotin‐labeled	antibody	cocktail	of	lineage‐
specific	 antibodies	 (CD5,	 CD45R,	 CD11b,	 Gr‐1	 and	 Ter‐119),	 followed	 by	 anti‐biotin	
MicroBeads,	according	to	the	manufacturer's	instructions	(mouse	lineage	depletion	kit).	
Lineage‐negative	 enriched	 cells	were	 resuspended	 in	 DMEM	 supplemented	with	 10%	
FCS	 and	100	ng/ml	hTPO	and	 incubated	 for	3	days	 at	 37°C	 to	 induce	megakaryocytic	
differentiation.	
Isolation and stimulation of murine megakaryocytes 
After	3	days	of	culture,	the	cell	suspension	containing	differentiated	MKs	was	aspirated	
and	 overlaid	 on	 a	 two‐step	 BSA	 gradient	 (1.5%	 and	 3%)	with	minimal	 agitation	 and	
were	incubated	for	30‐45	minutes	at	room	temperature.	The	cells	sedimenting	through	
the	 lower	 BSA	 gradient	was	 observed	 by	 eyes	 (see	 figure	 5.15).	When	 the	 pellet	was	
formed,	the	upper	phase	(almost	all	liquid	above	the	formed	pellet)	was	removed	gently.	
The	 pellet	 was	 resuspended	 in	 DMEM	 supplemented	 with	 10%FCS	 and	 left	 either	
unstimulated	or	stimulated	at	37°C	for	3	hours	with	1	µM	ionomycin.	
	
Preparation of cytospins and May‐Grünwald Giemsa staining 
0.05‐0.1	x	106	cells	suspended	in	medium	(max.	75µl)	were	mixed	with	one	volume	of	
cytospin	buffer	(20%	BSA	and	10%	FCS	in	PBS)	and	spun	(500	rpm	for	5	minutes)	onto	
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a	 Shandon	 Cytospin	 slide	 (Thermo	 Fisher	 Scientific	 GmbH,	 Dreieich,	 Germany)		
according	 to	 the	 standard	 cytospin	protocol.	 Samples	were	 air‐dried	 and	 stained	with	
standard	May‐Grünwald	 Giemsa	 staining	 and	mounted	 in	Merckoglas.	 Cytospins	were	
analyzed	using	a	Nikon	100x/1.40	objective	and	photographed	with	a	Digital	Sight	DS‐
5M	camera.	Images	were	captured	with	the	NIS‐Elements	D	Imaging	software.	
	
4.3.1				Co‐culture	experiments	
Co‐culture  of  human megakaryocytic  cells  and  Jurkat  T  cells  for  apoptosis 
experiments 
Co‐culture	 experiments	 were	 performed	 to	 determine	 the	 induction	 of	 apoptosis	 in	
Jurkat	T	cells	by	CMK	megakaryocytic	cells.	CMK	cells	(effectors)	were	first	pre‐labeled	
with	CFSE	and	then	remained	either	untreated	or	were	stimulated	with	1	µM	ionomycin	
in	the	presence	or	absence	of	CsA.	After	6	hours	of	stimulation,	 the	cells	were	washed	
twice	 with	 PBS	 to	 remove	 the	 stimulus.	 The	 cells	 were	 then	 mixed	 with	 Jurkat	 cells	
(targets)	in	an	effector‐to‐target	ratio	(E:T)	of	10:1.	In	selected	experiments,	neutralizing	
antibodies	 against	 Fas	 (ZB4)	 or	 FASLG	 (NOK‐1)	 were	 added	 at	 a	 concentration	 of	
1µg/ml	and	5µg/ml,	respectively,	during	the	co‐culture.	After	20	hours	of	co‐incubation,	
the	cells	were	harvested,	stained	with	annexin	V/	7AAD,	and	the	apoptosis	rate	of	 the	
Jurkat	 cells	 were	 analyzed	 by	 flow	 cytometry.	 CFSE	 was	 used	 to	 gate	 out	 the	 CMK	
effector	 cells	 (see	 figure	 5.14).	 As	 positive	 control,	 Jurkat	 cell	 mono‐cultures	 were	
incubated	 with	 a	 stimulating	 antibody	 against	 Fas	 (CH‐11)	 at	 a	 concentration	 of	
20ng/ml	in	the	presence	or	absence	of	ZB4.	
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4.4 Mice	
	
NFATc2‐/‐	 and	wild	 type	mice	 (C57BL/6	 background)	were	 held	 under	 pathogen‐free	
conditions	at	the	animal	facility	of	the	Technical	University	of	Dresden.	Before	sacrifice,	
animals	were	anesthetized	by	an	intraperitoneal	injection	of	a	combination	of	ketamine	
and	xylazine.	All	animal	protocols	were	approved	by	the	governmental	and	institutional	
animal	care	committees.	
	
Transplantation experiments 
Bone	marrow	was	flushed	from	both	femora	and	tibiae	of	NFATc2‐/‐	and	wild‐type	mice	
by	means	of	 a	23‐gauge	needle.	Cell	 suspensions	were	passed	 through	a	70	µm	nylon	
mesh	cell	strainer	to	obtain	single	cell	suspensions.	Afterwards,	the	cells	were	incubated	
with	 a	 biotin‐labeled	 antibody	 cocktail	 of	 lineage‐specific	 monoclonal	 antibodies,	
followed	by	anti‐biotin	MicroBeads	as	described	above,	according	to	the	manufacturer's	
instructions.	 Lineage‐negative	 enriched	 cells	 were	 then	 labeled	 with	 Sca‐1	 and	 cKit	
antibodies.	 Lin‐/Sca‐1+/cKit+	 (LSK)	 cells	 were	 isolated	 using	 FACS	 sorter.	 Thirty	
thousand	 LSK	 cells	were	 resuspended	 in	 200µl	 of	 PBS+5%FCS	 and	 then	 injected	 into	
retro‐orbital	venous	sinuses	of	lethally	irradiated	(8	Gy)	mice	without	anesthesia.	
	
Analysis of transplanted mice 
After	 a	 period	 of	 6‐8	months	 post‐transplantation,	 transplanted	mice	were	 sacrificed.	
The	 peripheral	 blood,	 BM	 as	well	 as	 spleen	 and	 liver	 cells	 of	 transplanted	mice	were	
collected	 for	 different	 hematological	 analysis.	 The	 peripheral	 blood	 was	 collected	 by	
retro‐orbital	 bleeding.	 Complete	 blood	 counts	 were	 performed	 using	 Sysmex.	
Cytomorphological	analysis	of	peripheral	blood,	BM	and	spleen	cells	were	performed	by	
assessing	blood	smears	as	well	as	BM	and	spleen	cytospins	stained	with	May‐Grünwald	
Giemsa	and	confirmed	by	 flow	cytometry.	Slides	were	examined	by	a	 light	microscope	
(Nikon).	Images	were	captured	using	Digital	Sight	DS‐5M	camera	and	the	NIS‐Elements	
D	Imaging	software.	
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Colony forming assays 
Single	 cell	 suspensions	 collected	 from	BM,	 spleen	and	 liver	of	 transplanted	mice	were	
resuspended	 in	 RPMI	 medium	 (supplemented	 with	 10%FCS	 and	 1%	 pen/strep)	 and	
mixed	 with	 methylcellulose‐based	 semisolid	 (MethoCult)	 medium	 according	 to	 the	
instructions	 provided	 by	manufacturer.	 Hematopoietic	 progenitor	 cells	were	 assessed	
by	 the	 number	 of	 burst‐forming	 units‐erythrocytes	 (BFU‐E),	 colony‐forming	 units‐
granulocyte/macrophage	 (CFU‐GM),	 CFU‐granulocyte	 (CFU‐G),	 and	 CFU‐macrophage	
(CFU‐M).		0.1x106		BM	cells,	1x106		splenocytes		and	1x106		liver	cells	were	cultured	for	
12	days	in	1	ml	MethoCult	GF	M3434	(for	CFU‐G,	CFU‐M,	CFU‐GM,	BFU‐E).	The	number	
of	 CFU‐megakaryocytes	 (CFU‐MK)	 was	 determined	 by	 culturing	 2.2x106	 BM	 cells	 or	
11x106	splenocytes	for	10	days	in	1	ml	Megacult	 	medium	containing	collagen	solution	
and	 supplemented	 with	 cytokine	 cocktail	 (50ng/ml	 rhTPO,	 10ng/ml	 rhIL‐3,	 20ng/ml	
rhIL‐6).	
	
Homing assays 
Bone	marrow	was	 flushed	 from	both	 femora	and	 tibiae.	Cell	 suspensions	were	passed	
through	a	70	µm	nylon	mesh	cell	strainer	to	obtain	single	cell	suspensions.	Afterwards,	
the	 cells	 were	 incubated	 with	 biotin‐labeled	 antibody	 cocktail	 of	 lineage‐specific	
monoclonal	antibodies	(CD5,	CD45R,	CD11b,	Gr‐1	and	Ter‐119),	followed	by	anti‐biotin	
MicroBeads,	according	to	the	manufacturer's	instructions	(mouse	lineage	depletion	kit).	
Lineage‐negative	 enriched	 cells	 were	 labeled	 with	 1	 mM	 CFSE	 in	 accordance	 to	 the	
manufacturer’s	 instructions.	 Cells	 were	 then	 injected	 into	 the	 retro‐orbital	 venous	
sinuses	 of	 3‐months‐old	 C57BL/6	mice	 that	 had	 been	 lethally	 irradiated	 (8	 Gy).	Mice	
were	 then	 killed	 20	 hours	 after	 injection	 and	 the	 numbers	 of	 homed	 cells	 were	
measured	in	the	BM	through	the	detection	of	CFSE+	cells	by	flow	cytometry.	The	number	
of	CFSE+	cells	was	also	analyzed	in	the	peripheral	blood	as	control.	
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4.5 Protein	analysis	
	
Western blot analysis 
40	 µg	 of	 protein	 per	 sample	 was	 extracted	 and	 mixed	 with	 loading	 buffer,	 then	
denatured	 at	 95°C	 for	 5	 minutes.	 Sodium	 dodecyl	 sulfate‐polyacrylamide	 gel	
electrophoresis	 (SDS‐PAGE)	 was	 performed	 according	 to	 standard	 procedures.	 For	
Western	blotting	of	FASLG,	10%	acrylamide	gel	was	used.	The	gel	was	run	with	20	mA	
constant	 current.	 The	 separated	 proteins	 were	 transferred	 to	 Hybond‐ECL	
Nitrocellulose	Membrane	(75	mA/gel,	1	h),	and	unspecific	binding	sites	were	blocked	in	
5%	non‐fat	dry	milk	powder	and	0.1%	Tween20	in	PBS	for	1	hour	 in	RT	on	a	shaking	
plate.	Membranes	were	 stained	overnight	with	 antibodies	 to	 FASLG	 (G247‐4)	 (diluted	
1:500)	and	ß‐actin	(1:4000,	as	loading	control),	followed	by	HRP‐conjugated	anti‐mouse	
antibody	 (1:2000)	 after	 3	 times	 	 washing	 for	 5	 minutes	 with	 washing	 buffer	 (0.1%	
Tween20	 in	 PBS)	 to	wash	 away	 unbound	 antibody.	Membranes	were	 then	 developed	
using	 the	 ECL	 (enhanced	 chemiluminescence)	 or	 the	 ECL	 Plus	 Western	 Blotting	
detection	kit	according	to	the	instructions	of	the	kit.	
 
Immunofluorescence 
Subcellular	localization	of	FASLG	protein	was	analyzed	by	immunofluorescence	staining	
of	 cytospin	 preparations.	 Culture‐derived	 MKs	 were	 mixed	 with	 cytospin	 buffer	 and	
spun	on	round	(Ø 15	mm)	coverslips	according	to	the	standard	cytospin	protocol.	The	
coverslips	were	 further	 processed	 in	 12‐well	 plates	 starting	with	 a	 paraformaldehyde	
(3%)	 fixation	 step.	 After	 removing	 the	 fixative	 reagent,	MKs	were	washed	 twice	with	
washing	 solution	 containing	 0.5%	 Nonidet	 P‐40	 for	 cell	 permeabilization	 and	 0.01%	
sodium	azide	(NaN3)	as	a	preservative	in	PBS.	After	samples	were	blocked	by	10%	FCS	
added	 to	 washing	 solution,	 FASLG	 primary	 antibody	 was	 diluted	 (1:200)	 in	 blocking	
solution	 and	 added	 to	 the	wells.	 30	minutes	 after	 staining	 the	 samples	were	washed	
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twice	and	a	Cy3‐labeled	secondary	antibody	(1:1000	diluted)	was	added.	After	washing	
steps,	samples	were	stained	with	an	anti‐CD61‐FITC	FACS	antibody	(diluted	1:500)	and	
were	 counterstained	 with	 DAPI	 (diluted	 1:2500).	 Cytospins	 were	 then	 mounted	 in	
ProLong	 Gold	 anti‐fade	 reagent	 and	 analyzed	 and	 photographed	 with	 a	 Nikon	
fluorescence	 microscope	 attached	 to	 an	 IMAC	 S30	 Video	 CCD	 camera.	 Images	 were	
acquired	and	processed	with	the	Isis	software.	
	
Flow cytometry analysis 
For	detection	of	FASLG	on	the	cell	surface,	the	cells	were	incubated	with	a	control	or	a	
biotin‐conjugated	anti‐FASLG	monoclonal	antibody	for	30	minutes	on	ice,	washed	twice	
with	PBS,	and	 incubated	on	 ice	 for	30	minutes	with	streptavidin	(1:100	diluted).	After	
two	 final	 washes,	 the	 cells	 were	 resuspended	 in	 PBS	 and	 analyzed	 on	 FACSCalibur	
Cellquest	 software.	 In	 apoptosis	 experiments,	 apoptotic	 cells	 were	 quantified	 by	
assessing	the	membrane	phosphatidylserine	exposure	of	the	cells	using	double‐staining	
with	 the	 annexin	 V‐APC	 staining	 kit	 and	 7AAD	 according	 to	 the	 manufacturer’s	
instructions.	Events	were	collected	on	a	FACScan	and	analyzed	by	Cellquest	software.	
	
	
	
4.6	 Histological	analysis	
	
Histological analysis of bone marrow 
Femora	of	NFATc2‐/‐	and	wild	type	mice	were	fixed	in	4%	PBS‐buffered	formalin	for	24	
h	 and	 then	 were	 decalcified	 in	 Osteosoft.	 Following	 dehydration	 with	 an	 ascending	
ethanol	 series	 and	 xylol,	 the	 tissues	 were	 embedded	 in	 paraffin.	 The	 sections	 were	
stained	with	hematoxylin‐eosin	 (H&E)	and	Gomori	 for	visualization	of	 reticular	 fibers.	
Slides	were	examined	and	imaged	using	a	light	microscope.	
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Acetylcholinesterase staining of megakaryocytic cells 
All	 procedures	 were	 performed	 exactly	 according	 to	 the	 protocol	 provided	 by	 the	
manufacturer	 (Megacult‐C).	 Briefly,	 the	 slides	 containing	 CFU‐MK	 were	 fixed	 in	 cold	
acetone	 and	 allowed	 to	 air	 dry.	 Acetylcholinesterase	 substrate	 solution	was	 prepared	
freshly	(acetylthiocholiniodide	was	dissolved	in	sodium	phosphate	buffer,	then	sodium	
citrate,	copper	sulfate	and	potassium	ferricyanide	were	added).	Slides	were	incubated	in	
the	 staining	 solution	 for	 4	 hours	 and	 then	were	 fixed	with	 95%	 ethanol,	 rinsed	with	
lukewarm	 water	 and	 air	 dried.	 Harris’	 hematoxylin	 counterstaining	 was	 done	 for	 30	
minutes.	Slides	were	evaluated	by	light	microscopy.	
	
4.7 RNA	sequencing	
4.7.1  Sample preparation 
Total	 RNA	 was	 extracted	 using	 Trizol	 according	 to	 the	 manufacturer’s	 instructions.	
RNAs	from	6	biological	replicates	from	either	stimulated	or	unstimulated	samples	were	
assessed	for	purity	and	integrity	using	a	NanoDrop	2000	spectrophotometer	and	a	2100	
Bioanalyzer,	respectively.		
Sequencing	libraries	were	prepared	at	the	'Deep	sequencing	facility	SFB	655',	Dresden,	
Germany.	Briefly,	mRNA	was	isolated	by	poly‐dT‐enrichment	using	the	Oligo	(dT)‐based	
µMACS	 mRNA	 isolation	 kit	 according	 to	 the	 manufacturer’s	 instructions,	 followed	 by	
DNase	treatment	and	mRNA	purification	using	Agencourt	RNAclean	XP‐beads.	After	first	
and	 second	 strand	 cDNA	 synthesis,	 End‐pair	 and	 A‐tailing	 of	 double	 stranded	 cDNA	
were	 performed	 according	 to	 the	 manufacturer's	 instructions.	 After	 adaptor	 ligation,	
large	 scale	 amplification	 of	 library	 constructs	 was	 performed.	 Thereafter,	 cDNA	 was	
size‐selected	 on	 2%	 agarose	 (E‐Gel)	 and	 the	 libraries	 were	 quantified	 using	 Qubit	
dsDNA	HS	 assay	 kit.	 Single	 read	 50‐bp	 sequencing	was	 performed	 on	 Illumina	 HiSeq	
2000.		
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4.7.2  Analysis of RNA sequencing results 
Mapping, normalization and sequence analysis 
Reads	were	mapped	against	murine	reference	genome	and	splice	junction	library	(mm9	
transcriptome)	 using	 BWA	 (http://bio‐bwa.sourceforge.net/bwa.shtml).	 Counts	 per	
gene	were	computed	based	on	the	Ensembl	61	annotation	for	mm9.	The	counts	per	gene	
were	 then	 normalized	 by	 DESeq	 R	 package	 (http://bioconductor.org/packages/	
release/bioc/html/DESeq),	based	on	the	library	size.		
	
Differential expression (DE) analysis 
To	 test	 for	differential	 expression	comparisons	among	 four	experimental	 conditions	R	
statistical	package	DESeq	was	used.	
 
Biological pathways analysis 
Biological	enrichment	was	performed	by	Miltenyi	Biotec,	GmbH	using	TreeRanker.	 "P‐
values"	 which	 indicate	 the	 significance	 of	 enrichment,	 were	 computed	 with	 Fisher's	
exact	test,	followed	by	Benjamini‐Hochberg	correction	for	multiple	testing.	
	
4.8	 Statistical	analysis	
Results	 are	 presented	 as	 means	 ±	 standard	 error	 of	 the	 mean	 (SEM).	 Statistical	
significances	were	calculated	with	a	t	test	and	chi‐square	test	using	the	GraphPad	Prism	
software.	P‐values	<0.05	were	considered	statistically	significant.		
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5 Results 
	
5.1	 Role	of	NFATc2	in	hematopoietic	progenitor	cells	
	
We	have	previously	shown	that	the	calcineurin‐dependent	transcription	factor	NFATc2	
is	 highly	 expressed	 in	 hematopoietic	 stem	 cells	 and	 regulated	 during	 myeloid	
commitment	in	a	lineage‐specific	manner.79,	143	
In	 a	 further	 recent	 study	 we	 showed	 that	 aged	 mice	 lacking	 NFATc2	 develop	
hematological	 and	 osteological	 abnormalities	 such	 as	 anemia	 and	 thrombocytopenia,	
BM	 hypoplasia	 (with	 megakaryocytic	 and	 erythroid	 lineages	 being	 most	 affected),	
ossification	 of	 the	BM	 space,	 as	well	 as	 an	 increased	 formation	 of	 reticular	 fibers	 and	
extramedullary	hematopoiesis	in	the	spleen	and	liver.	
	The	 phenotype	 of	 these	 mice	 suggested	 that	 the	 lack	 of	 NFATc2	 apparently	 affects	
either	hematopoietic	cells	or	cells	of	their	microenvironment,	or	the	interaction	of	these	
two	 compartments.	 Whether	 these	 abnormalities	 result	 from	 defects	 in	 the	
hematopoietic	stem	and/or	progenitor	cells	or	 from	BM	stroma	malfunctioning	 in	 this	
study	remained	open.	In	order	to	find	out	the	relative	contribution	of	hematopoietic	and	
stromal	 cells	 to	 the	 phenotype	 of	 the	 NFATc2‐deficient	 mice,	 we	 designed	 a	
transplantation	study	in	which	functional	HSCs	were	isolated	based	on	their	phenotype.	
HSCs	 are	 characterized	 by	 the	 lack	 of	 expression	 of	 a	 number	 of	 cell	 surface	markers	
which	 are	 normally	 found	 on	 differentiating	 or	 mature	 blood	 cells	 (Lin‐,	 lineage	
negative)	while	displaying	high	 levels	of	 Sca1	and	 c‐kit.166,	 167	 	 	 This	population	of	BM	
cells	 is	referred	to	as	the	LSK	compartment	(Lin‐/Sca1+/c‐kit+)	and	has	been	shown	to	
sufficiently	contribute	to	reconstitution	and	repopulation	of	lethally	irradiated	hosts.168		
Thus,	 immunomagnetically‐purified	 NFATc2‐knockout	 (KO)	 LSK	 cells	 (HSCs)	 were	
transplanted	 into	 lethally	 irradiated	wild	type	(WT)	mice,	and	vice	versa.	After	a	post‐
transplantation	 period	 of	 6‐8	 months	 which	 allowed	 the	 phenotype	 to	 develop,	
peripheral	 blood,	 BM	 as	 well	 as	 spleen	 and	 liver	 of	 the	 transplanted	 animals	 were	
analyzed	and	compared	to	WT	and	KO	mice	transplanted	with	control	cells	(figure	5.1).	
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Figure	5.1.	 Schematic	 representation	of	 the	 transplantation	 study.	Bone	marrow	
cells	were	 flushed	out	of	 femora	and	 tibia	of	WT	and	NFATc2‐/‐	mice.	Lineage	positive	
cells	 were	 depleted	 with	 lineage	 depletion	 kit	 and	 the	 lineage‐negative‐enriched	
population	 of	 the	 cells	was	 labelled	with	 antibodies	 against	 hematopoietic	 progenitor	
markers	 (anti‐Sca1‐PE	and	anti‐cKit‐APC).	Cells	which	were	positive	 for	both	markers	
were	 sorted	 by	 flow	 cytometry	 and	 injected	 into	 lethally	 irradiated	 (8	 Gy)	 WT	 or	
NFATc2‐deficient	 mice.	 After	 a	 post‐transplantation	 period	 of	 6‐8	months,	 peripheral	
blood,	 BM	 as	well	 as	 spleen	 and	 liver	 of	 the	 transplanted	 animals	were	 analyzed	 and	
compared	to	WT	and	KO	mice	transplanted	with	control	cells.	
	
	
5.1.1	 Reciprocal	 transplantation	experiments:	effects	on	peripheral	blood	
parameters.			
	
In	 order	 to	 evaluate	 the	 impact	 of	 transplantation	 on	 hematopoiesis,	 we	 performed	
complete	blood	 counts	 of	 all	 four	 groups	of	 transplanted	mice	 i.e.,	WTWT,	WTKO	
(WT	HSC	transplanted	into	KO	host),	KOKO	and	KOWT	(KO	HSC	transplanted	into	
WT	host).	The	 results	 (shown	 in	 figure	5.2	and	summarized	 in	 table	5.1)	 showed	 that	
WT	 mice	 transplanted	 by	 HSCs	 from	 NFATc2‐deficient	 mice	 (KOWT)	 were	 anemic	
with	 reductions	 in	 all	parameters	of	 the	erythroid	 lineages,	namely	erythrocyte	 (RBC)	
number,	hemoglobin	(HGB)	and	hematocrit	(HCT)	when	compared	with	those	observed	
in	 non‐transplanted	WT	mice	 or	 in	WT	mice	 transplanted	with	WT	HSCs	 (WTWT).	
Conversely,	transplantation	of	WT	HSCs	into	KO	recipients	(WTKO)	partially	restored	
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the	pathological	blood	parameters	observed	in	KO	control	mice	(KOKO)	(table	5.1	and	
figure	5.2A).		
Previously,	 it	 has	 been	 reported	 that	 mice	 lacking	 NFATc2	 demonstrate	 increased	
lymphoproliferative	responses.9,	101	As	expected,	KOKO	control	mice	revealed	a	higher	
number	of	lymphocytes	in	comparison	to	WTWT	controls.	A	mild	lymphocytosis	was	
also	noticed	in	the	peripheral	blood	of	KOWT	transplanted	mice	(table	5.1).		
Another	observation	in	aged	NFATc2‐KO	mice	was	the	fact	that	their	anemic	phenotype	
was	accompanied	by	reticulocytosis.84	The	pathomechanism	is	unclear,	but	may	be	the	
results	of	extramedullary	hematopoiesis.	 In	contrast	to	WTWT	mice,	complete	blood	
counts	of	KOWT	mice	revealed	an	increase	in	the	number	of	reticulocytes,	evident	by	
the	 polychromatic	 appearance	 of	 reticulocytes	 (arrows)	 in	 their	 peripheral	 blood	
smears,	resembling	KOKO	controls	(figure	5.2C)		
On	 the	 other	 hand,	 KOWT	 mice	 (compared	 to	 WTWT	 mice)	 showed	 a	 strong	
reduction	in	their	platelet	counts	(figure	5.2	B),	whereas	the	transplantation	of	WT	HSCs	
restored	 the	 blood	 platelet	 number	 of	 NFATc2‐KO	 recipients	 nearly	 to	 the	 WT	 level	
(table	5.1	and	figure	5.2B)			
Table	5.1.	Hematologic	parameters	of	transplanted	mice	
	
	
WTWT	 KOWT KOKO WTKO	
RBC	(1012/L)	 7.32±0.29	 6.15±0.69 5.60±0.49 7.07±0.41	
HGB	(	mmol/L)	 6.58±0.33	 5.67±0.58 4.98±0.43 6.5±0.40	
HCT	(%)	 38.33±1.77	 33.64±2.60 30.65±2.09 36.63±1.51	
PLT	(109/L)	 636.42±89.51 365.42±69.24 473.62±100.11 603.33±106.24	
Reticulocytes	(109/L)	 313.52±37.91 405.14±64.52 513.07±99.09 218.92±51.47	
WBC	(109/L)	 2.31±0.52	 2.88±0.88 3.79±0.82 2.78±0.66	
Differential	counts	
(108/L):	
	 	
Neutrophils	 3.7	 2.6 3.2 4.1	
Lymphocytes	 18.3	 24.8 33 22.5	
Monocytes	 0.88	 1.15 1.51 0.94	
Number	of	mice	 7	 7 8 6	
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Figure	 5.2.	 Anemia,	 thrombocytopenia	 and	 reticulocytosis	 in	 WT	 recipients	
transplanted	 with	 NFATc2‐deficient	 HSCs.	 	 (A)	 Red	 blood	 cell	 parameters	 in	 the	
peripheral	 blood	 of	 transplanted	mice.	 Red	 blood	 cells	 (RBC),	 hemoglobin	 (HGB)	 and	
hematocrit	 (HCT).	 Shown	 are	 means	 ±SEM.	 *	 p<0.05,	 **p<0.01	 (B)	 Peripheral	 blood	
platelet	numbers	in	transplanted	mice.	(C)	Reticulocytes	in	peripheral	blood	smears	of	
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transplanted	 mice.	 Arrows	 illustrate	 the	 polychromatic	 reticulocytes	 in	 the	 blood	
smears.	n=7	(WTWT),	n=7	(KOWT),	n=8	(KOKO),	n=6	(WTKO).		
	
5.1.2	 Reciprocal	 transplantation	 experiments:	 effects	 on	 bone	 marrow	
parameters.		
	
Hematopoietic	stem	cell	transplantation	from	NFATc2‐KO	donors	was	shown	to	induce	
anemia	and	thrombocytopenia	in	WT	recipients.	As	the	origin	of	hematopoiesis,	we	next	
examined	 the	 BM	 compartments	 of	 transplanted	 mice.	 Transplantation	 of	 NFATc2‐
deficient	 HSCs	 into	WT	 recipients	 (KOWT)	 induced	 BM	 hypoplasia	 (figure	 5.3A)	 in	
comparison	to	WTWT	control	animals,	while	in	KO	mice	transplanted	with	WT	HSCs	
(WTKO),	 total	 BM	 cell	 counts	 were	 significantly	 increased	 compared	 to	 KOKO	
control	 mice	 (figure	 5.3A).	 Cytological	 differentiation	 of	 the	 extracted	 BM	 cells	 of	
KOWT	mice	revealed	that	the	reduction	in	BM	cells	was	most	pronounced	in	erythroid	
(figure	 5.3B)	 and	megakaryocytic	 (figure	 5.3C)	 lineages	 in	 comparison	 to	 the	 control	
animals.	In	contrast,	no	significant	effect	of	transplantation	was	detected	in	the	absolute	
number	of	lymphocytes	(figure	5.3B).	
Histological	analysis	of	 the	femora	of	WT	mice	transplanted	by	NFATc2‐deficient	HSCs	
revealed	that	bone	trabeculae,	albeit	 to	a	variable	extent,	had	 formed	in	the	BM	cavity	
(figure	 5.3D).	 This	 observation	 was	 in	 sharp	 contrast	 to	 the	 BM	 space	 of	 all	 non‐
transplanted	WT	mice	as	well	as	of	WTWT	control	animals.	To	examine	whether	the	
ossification	of	the	BM	cavity	in	KOWT	mice	was	associated	with	further	alterations	in	
the	animals'	extracellular	matrix,	BM	sections	of	all	four	types	of	transplanted	mice	were	
stained	 for	 the	 presence	 of	 reticular	 fibers.	 In	 addition	 to	 the	 presence	 of	 bone	
trabeculae,	 increased	 formation	 of	 reticular	 fibers	 was	 found	 in	 the	 BM	 space	 of	
KOWT	mice,	while	neither	WT	nor	WT	WT	control	mice	showed	any	abnormalities	
in	their	BM	phenotype	(figure	5.3E).	
In	order	to	further	characterize	the	BM	hematopoietic	compartment	of	the	transplanted	
mice,	we	analyzed	the	frequency	of	hematopoietic	progenitor	cells	in	this	organ.	Colony‐
forming	 assays	 showed	 that	 the	 numbers	 of	 erythroid,	 granulocytic/monocytic	 and	
megakaryocytic	precursors	per	 femur	were	decreased	 in	WT	mice	receiving	NFATc2‐/‐	
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HSCs	(KO	WT)	in	comparison	to	WT	WT	controls	(figure	5.4).	Thus,	the	reduction	of	
hematopoietic	progenitors	in	these	mice	(KO	WT)	correlated	with	the	reduction	of	all	
myeloid	cells	in	the	BM	and	the	hematological	abnormalities	in	the	blood.	
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Figure	 5.3.	 Bone	 marrow	 hypoplasia	 and	 bone	 abnormalities	 in	 WT	 mice	
transplanted	with	NFATc2‐deficient	HSCs.	 	(A)	Total	number	of	BM	cells	per	femur.	
Shown	are	means	±SEM.	(B)	Differentials	of	BM	cells,	counted	on	cytospin	slides.	Blue,	
purple	and	yellow	portions	of	the	pie	chart	represent	erythroid,	granulocytic/monocytic	
cells	and	lymphocytes,	respectively.	(C)	Number	of	MKs	per	femur	of	transplanted	mice.	
Shown	are	means	±SEM.	*	p<0.05,	**p<0.01,	***p<0.001.	(D,	E)	Histological	analysis	of	
BM	of	transplanted	mice.	Bone	marrow	sections	were	stained	with	H&E		(D)	and	Gomori	
(E)	and	analyzed	by	microscopy.	Trabecular	bone	(D)	as	well	as	reticular	fiber	formation	
(stained	gray	 in	E)	was	observed	in	KOWT	mice	as	well	as	KOKO	control	animals.	
n=7	(WTWT),	n=7	(KOWT),	n=8	(KOKO),	n=6	(WTKO).		
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Figure	5.4.	Decreased	number	 of	 colony‐forming	 cells	 in	WT	mice	 transplanted	
with	NFATc2‐KO	HSCs.	 	Colony‐forming	assays	(CFU‐G,	CFU‐M,	CFU‐GM,	BFU‐E	and	
CFU‐MK)	were	performed	with	BM	cells	of	transplanted	mice.	The	numbers	of	colonies	
per	 femur	 of	 transplanted	 mice	 are	 shown.	 n=7	 (WTWT),	 n=7	 (KOWT),	 n=8	
(KOKO),	n=6	(WTKO).	
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5.1.3	 Reciprocal	 transplantation	 experiments:	 effects	 on	 extramedullary	
hematopoiesis.	
Mice	 lacking	 NFATc2	 are	 characterized	 by	 splenomegaly	 and	 extramedullary	
hematopoiesis.84	In	order	to	analyze	extramedullary	hematopoiesis	in	our	transplanted	
model,	we	next	 focused	on	 the	 spleens	and	 livers	of	WT	mice	 transplanted	with	HSCs	
from	NFATc2	deficient	mice	(KOWT).	Enlarged	spleen	as	well	as	a	drastic	increase	in	
the	number	of	 splenocytes	was	observed	 in	KOWT	mice	 in	 comparison	 to	WTWT	
control	animals	(figure	5.5A).		
Further	analysis	of	the	spleen	cells	of	KOWT	mice	showed	that,	while	all	myeloid	and	
lymphoid	had	expanded	numerically	in	comparison	to	control	WT	mice	(WTWT),	the	
relative	 proportion	 of	 erythroid	 and	 megakaryocytic	 cells	 had	 increased	 over	 other	
lineages	(figure	5.5B).	Therefore,	 in	KOWT	mice	(as	well	as	 in	KOKO	controls)	the	
ratio	of	myeloid	to	lymphoid	cells	had	shifted	in	favour	of	the	myeloid	compartment.	
Our	 recent	 study	 on	 the	 steady‐state	 hematopoiesis	 in	NFATc2‐/‐	mice	 suggested	 that	
while	the	frequency	of	hematopoietic	progenitor	cells	is	decreased	in	the	BM	of	KO	mice,	
these	 cells	 preserve	 their	 full	 ability	 to	 differentiate	 along	 the	 erythroid,	 granulocytic,	
and	megakaryocytic	lineages.84	 	We	analyzed	the	frequency	of	myeloid	progenitor	cells	
in	spleen	and	liver	of	transplanted	mice.	Colony	forming	assay	indicated	that	frequencies	
of	 granulocytic/monocytic	 (CFU‐GM/CFU‐G/CFU‐M),	 erythroid	 (BFU‐E)	 and	
megakaryocytic	 (CFU‐MK)	 progenitors	were	 all	 increased	 in	 spleens	 of	 KOWT	mice	
(resembling	 KOKO	 or	 non‐transplanted	 KO	 mice)	 compared	 to	 WTWT	 controls	
(figure	5.5C).		In	contrast,	the	frequency	of	colonies	(granulocytic/monocytic,	erythroid	
and	 megakaryocytic)	 was	 reduced	 in	 WTKO	 mice,	 which	 was	 consistent	 with	 the	
almost	normal	size	of	their	spleens	as	well	as	the	numbers	of	splenocytes,	compared	to	
those	 observed	 in	KOKO	 controls	 (figure	5.5C).	 	 Furthermore,	 colony	 forming	 assay	
results	 from	 the	 liver	 confirmed	 the	 presence	 of	 extramedullary	 hematopoiesis	 in	
KOWT	mice,	as	granulocytic/monocytic	(CFU‐GM/CFU‐G/CFU‐M)	and	erythroid	(BFU‐
E)	 progenitors	were	 increased	 in	 these	mice	 in	 comparison	 to	WTWT	 control	mice	
(figure	4.5D).		
	All	 together,	 these	 results	 show	 that	 most	 (if	 not	 all)	 abnormalities	 observed	 with	
respect	to	blood	and	BM	abnormalities	in	aged	NFATc2‐deficient	mice,84	can	be	induced	
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in	WT	host	by	the	transplantation	of	NFATc2‐deficient	HSCs.	This	includes	the	induction	
of	osteomyelosclerosis/osteomyelofibrosis	and	extramedullary	hematopoiesis.	
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Figure	 5.5.	 Splenomegaly	 and	 extramedullary	 hematopoiesis	 in	WT	 recipients	
transplanted	 with	 NFATc2‐deficient	 HSCs.	 (A)	 Number	 of	 splenocytes.	 (B)	
Differentials	of	spleen	cells.	Blue,	purple	and	yellow	portion	of	 the	pie	chart	represent	
erythroid,	 granulocytic/monocytic	 and	 lymphocytic	 cells,	 respectively.	 (C)	 Number	 of	
hematopoietic	 colonies	 (CFU‐G,	 CFU‐M,	 CFU‐GM,	BFU‐E)	 derived	 from	1x106	 cells	 and	
CFU‐MK	derived	from	11x106	cells	from	spleens.	(D)	Number	of	colonies	(CFU‐G,	CFU‐M,	
CFU‐GM,	BFU‐E)	derived	from	1x106	cells	 from	livers.	n=7	(WTWT),	n=7	(KOWT),	
n=8	(KOKO),	n=6	(WTKO).	*	
	
 
5.1.4 Homing of NFATc2-deficient HSCs into the bone marrow  
 
Homing	 is	a	process	 in	which	stem	and	progenitor	cells	migrate	from	the	blood	to	BM	
niches.89,	93	Next,	we	set	out	to	investigate	whether	the	reduced	cellularity	of	the	BM	of	
KO	as	well	 as	 transplanted	KOKO	and	KOWT	mice	may	be	 the	 consequence	of	 an	
altered	homing	of	HSCs	to	the	correct	BM	microenvironment.	To	examine	this,	purified	
lineage	negative	BM	cells	 isolated	 from	either	WT	or	NFATc2‐/‐	mice	were	pre‐stained	
with	fluorescent	CFSE	dye	(figure	5.6	A)	followed	by	the	injection	of	500,000	cells	into	
the	retro‐orbital	venous	sinus	of	 lethally	 irradiated	recipient	mice.	Twenty	hours	after	
infusion,	 BM	 cells	 were	 collected.	 Fluorescent	 events	 were	 evaluated	 by	 high‐speed	
FACS	analysis.	No	difference	in	the	number	of	WT	and	NFATc2	KO	cells	seeding	to	the	
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marrow	space	was	found	(figure	5.6	B).	Moreover,	CFSE+	cells	were	undetectable	in	the	
blood	stream	of	any	of	the	transplanted	groups	suggesting	complete	homing	of	the	cells	
(figure	5.6C).	 	As	a	consequence,	 the	homing/migration	capability	of	NFATc2‐deficient	
hematopoietic	 progenitors	 seems	 to	 be	 preserved	 and	 not	 to	 be	 influenced	 by	 the	
presence	or	absence	of	NFATc2	in	these	cells.	
	
	
	
	
Figure	5.6.	Normal	homing	of	NFATc2‐deficient	hematopoietic	progenitor	cells	to	
the	bone	marrow.	(A)	Lineage	negative	cells	were	isolated	from	the	BMs	of	WT	and	KO	
mice.	The	 cells	were	 then	 labeled	with	CFSE	viable	dye.	The	efficiency	of	 labeling	was	
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evaluated	by	flow	cytometry.	(B)	and	(C)	High‐speed	flow	cytometry	analysis	of	CFSE‐
positive	 cells	 in	 the	 BM	 (B)	 and	 peripheral	 blood	 (C)	 of	 transplanted	mice	 20	 h	 after	
injection.	The	number	of	CFSE+	cells	was	estimated	using	the	same	gate	(here	shown	as	
R3)	 as	 shown	 in	 (A).	 Results	 are	 representative	 of	 at	 least	 three	 independent	
experiments.	
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5.2	 Role	of	NFATc2	in	mature	megakaryocytes	
	
	
It	has	been	well	established	 that,	apart	 from	T	cells,	NFAT	 is	expressed	 in	a	variety	of	
different	 tissues,	 where	 it	 regulates	 the	 expression	 of	 genes	 involved	 in	 cellular	
processes	of	adaptation	and	differentiation.2,	3,	79	
Our	group	has	 recently	established	a	detailed	expression	pattern	of	 all	NFAT	genes	 in	
CD34+	 hematopoietic	 stem	 cells	 and	 during	 their	 differentiation	 into	 various	
hematological	 cell	 types.78,	 79	 This	 phenomenon	 was	 particularly	 evident	 for	 NFATc2,	
which	 in	 megakaryocytic	 cells	 was	 detected	 throughout	 differentiation	 at	 a	 level	
comparable	 to	 T	 cells,	 but	 was	 rapidly	 downregulated	 during	 the	 differentiation	 of	
neutrophils.		
Furthermore,	 NFATc2‐deficient	 mice	 suffer	 from	 thrombocytopenia.	 However,	
subsequent	studies	showed	that	calcineurin/NFAT	activation	is	dispensable	for	effective	
megakaryopoiesis.	 In	 contrast,	 in	 mature	 MKs,	 NFATc2	 regulates	 the	 expression	 of	 a	
number	of	megakaryocytic	genes	(such	as	RCAN1	[DSCR1]	and	CD40LG	[CD154]).126,	142,	
143	The	biological	consequence	of	this	finding,	however,	remains	unknown.	
In	the	current	study,	therefore,	we	set	out	to	define	the	role	of	NFATc2	in	mature	MKs	
further.	
	
	
5.2.1	 Calcium	ionophore	stimulation	leads	to	megakaryocyte	death	
	
We	first	addressed	the	question	of	whether	activation	of	the	calcineurin/NFAT	pathway	
affects	MK	viability.	NFAT	activation	is	regulated	via	dephosphorylation	in	a	calcineurin‐
dependent	manner.	Since	physiological	agonists	of	NFAT	signaling	in	MKs	are	unknown,	
we	used	the	pharmacological	agent	ionomycin,	a	calcium	ionophore	which	is	produced	
by	 the	 bacterium	 Streptomyces	Conglobattus.169	 Ionomycin	 treatment	 leads	 to	 a	 rapid	
rise	in	the	intracellular	levels	of	calcium,	which	activates	calcineurin	and	subsequently	
leads	to	the	activation	of	NFAT	(i.e.,	its	dephosphorylation	and	nuclear	translocation).78,	
170		
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To	 first	 test	 the	viability	 of	MKs	 in	 cell	 line	models,	megakaryocytic	Meg‐01	and	CMK	
cells	were	 left	either	untreated	or	treated	for	up	to	48	hours	with	 ionomycin.	 	For	cell	
viability	measurement,	the	colorimetric	MTT	assay	was	used	as	an	indirect	marker.	The	
MTT	assay	measures	the	metabolic	activity	of	the	cells	which	is	based	on	the	ability	of	
active	mitochondrial	dehydrogenase	to	convert	dissolved	(3‐[4,	5‐dimethylthiazol‐2‐yl]‐
2,	5‐diphenyltetrazolium	bromide;	MTT)	to	water‐insoluble	purple	formazan	crystals.		
As	shown	 in	 figure	5.7,	 treatment	with	 ionomycin	resulted	 in	a	significant	decrease	of	
the	MTT	 signal	 in	Meg‐01	 as	well	 as	 in	 CMK	 cultures,	 suggesting	 reduced	 viability	 in	
ionomycin‐treated	cells.	
	
	
	
	
Figure	5.7.	Ionomycin	stimulation	leads	to	megakaryocyte	death.		CMK	and	Meg‐01	
megakaryocytic	cells	were	treated	with	1	µM	ionomycin	for	0,	24	and	48	h,	respectively.	
Cell	 viability	 was	 determined	 by	 MTT	 assay.	 Shown	 are	 means	 ±SEM.	 *p<0.05	 and	
**p<0.01.		
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5.2.2	 Activation	 of	 the	 calcineurin	 pathway	 induces	 apoptosis	 in	
megakaryocytes.		
	
Programmed	 cell	 death	 –or	 apoptosis–	 is	 a	 process	 by	 which,	 in	 balance	 with	 cell	
proliferation,	homeostasis	of	a	cell	population	is	maintained.152,	171,	172	
In	 order	 to	 assess	 whether	 the	 reduction	 of	 cell	 viability	 of	 megakaryocytic	 cells	 in	
response	to	ionomycin	was	due	to	the	induction	of	programmed	cell	death,	we	analyzed	
the	 nuclear	 morphology	 of	 untreated	 and	 ionomycin‐treated	 CMK	 cells	 by	
epifluorescence	microscopy	after	nuclear	staining	with	DAPI	(figure	5.8A).	The	analysis	
was	extended	 to	primary	MKs	 (‘culture‐derived	megakaryocytes’)	 (figure	5.8B),	which	
were	 generated	by	 culturing	CD34+	hematopoietic	 progenitor	 cells	 in	 the	 presence	 of	
the	megakaryocytic	growth	factor	TPO.		Ionomycin‐treated	nuclei	of	both	CMK	cells	and	
culture‐derived	MKs	presented	clear	features	of	apoptosis	(figure	5.8A	and	B,	panels	ii),	
namely	apoptotic	bodies	(arrow	heads)	as	well	as	fragmented	and	condensed	chromatin	
(arrows).	 In	contrast,	nuclei	of	unstimulated	cells	remained	unremarkable	(figure	5.8A	
and	 B,	 panels	 i).	 To	 better	 quantify	 the	 pro‐apoptotic	 effect	 of	 ionomycin	 in	
megakaryocytic	 cells,	 we	 used	 the	 flow	 cytometric	 annexin	 V	 assay	 on	 untreated	 and	
ionomycin‐stimulated	 culture‐derived	 primary	 MKs.	 As	 expected,	 within	 24	 h,	
ionomycin	 treatment	resulted	 in	a	significant	 increase	 in	 the	percentage	of	annexin	V‐
positive	MKs,	as	compared	to	unstimulated	controls	(figure	5.8C,	left	and	middle	bars).	
These	results	demonstrate	that	ionomycin	induces	apoptosis	in	megakaryocytic	cells.	
To	 confirm	 that	 the	 effect	 of	 the	 calcium	 ionophore	was	mediated	 by	 calcineurin,	 the	
calcineurin	inhibitor	CsA	was	added	to	the	cultures	30	min	prior	to	the	stimulation.	CsA	
is	an	immunosuppressant	drug	used	to	block	NFAT	activation	(see	section	2.1.4).46,	55,	170,	
173,	174		The	addition	of	CsA	almost	completely	rescued	the	cells	from	ionomycin‐induced	
apoptosis,	 confirming	 the	 involvement	 of	 calcineurin	 in	 this	 process	 (figure	 5.8A,	 B,	
panels	iii,	and	figure	5.8C,	right	bar).	Together,	these	data	demonstrate	by	two	different	
methods	 (nuclear	 morphology	 and	 annexin	 V	 flow	 cytometry)	 that	 activation	 of	 the	
calcineurin	pathway	in	MKs	induces	programmed	cell	death	in	these	cells.	
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Figure	 5.8.	 Activation	 of	 the	 calcineurin	 pathway	 induces	 apoptosis	 in	
megakaryocytes.	(A)	CMK	cells	and	(B)	culture‐derived	primary	MKs	were	either	 left	
untreated	or	stimulated	with	1µM	ionomycin	for	24	h	in	the	presence	or	absence	of	the	
calcineurin	 inhibitor	 cyclosporin	 A	 (CsA).	 Morphological	 changes	 of	 the	 nuclei	 were	
analyzed	by	epifluorescence	microscopy	after	staining	with	DAPI.	Note	the	appearance	
of	 condensed	 chromatin	 (arrows)	 as	 well	 as	 fragmentation	 and	 apoptotic	 bodies	
(arrowheads)	in	the	nuclei	of	ionomycin‐treated	cells	indicating	apoptosis	of	these	cells.	
Scale	 bars	 represent	 10	 µm.	 (C)	 Culture‐derived	 MKs	 were	 either	 left	 untreated	 or	
stimulated	 with	 ionomycin	 for	 24	 h	 in	 the	 presence	 or	 absence	 of	 the	 calcineurin	
inhibitor	 CsA,	 as	 indicated.	 The	 frequency	 of	 apoptotic	 cells	 was	 determined	 by	 flow	
cytometric	 analysis	 of	 annexin	 V‐positive	 cells	 after	 24	 h	 of	 incubation.	 Statistical	
analysis	of	annexin	V‐positive	cells	of	at	 least	 four	 independent	experiments	 is	shown.	
Shown	are	means	±SEM.	*	p	<	0,	05.		
			
5.2.3 Apoptosis induction in megakaryocytes is dependent on NFAT activation 
 
Calcineurin	 is	 the	 key	 enzyme	 for	 NFAT	 activation,	 but	 calcineurin	 has	 also	 other	
substrates	and	affects	various	signaling	pathways	in	addition	to	NFAT.55,	57	To	determine	
if	apoptosis	 induced	by	activation	of	 the	calcineurin	pathway	 in	MKs	was	mediated	by	
NFAT	 or	 by	 other	 substrates,	 CMK	 cells	 were	 retrovirally	 transduced	 with	 either	 an	
NFATc2‐EGFP	 construct	 or	 with	 a	 vector	 encoding	 the	 peptide	 VIVIT‐GFP,	 a	 specific	
inhibitor	of	NFAT	activation.57,	175	NFATc2	was	chosen	out	of	the	NFAT	family	members	
because	 of	 its	 known	 expression	 in	 MKs.78,	 79	 Cells	 transduced	 with	 EGFP	 served	 as	
control.	 Control	 cells	 (CMK‐EGFP),	 cells	 overexpressing	 NFATc2	 (CMK‐NFATc2)	 and	
cells	unable	to	activate	any	NFAT	protein	(CMK‐VIVIT)	were	then	either	 left	untreated	
or	stimulated	with	 ionomycin	 in	 the	presence	or	absence	of	CsA,	and	 further	analyzed	
for	apoptosis	induction	(figure	5.9).	
Microscopic	examination	of	DAPI‐stained	nuclei	revealed	that	overexpression	of	NFATc2	
augmented,	 while	 expression	 of	 VIVIT	 suppressed	 apoptosis	 induction	 in	 CMK	 cells	
(figure	5.9A).	The	effect	of	NFATc2	overexpression	on	apoptosis	was	already	apparent	in	
unstimulated	 cells,	 thus	mimicking	 the	effect	 of	 ionomycin	 treatment	 (figure	5.9A,	 left	
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panel).	We	 confirmed	 these	 results	 by	 evaluating	 the	 apoptosis	 rate	 in	 an	 annexin	 V	
assay	 (figure	 5.9B).	 Ionomycin	 treatment	 significantly	 enhanced	 the	 apoptosis	 rate	 in	
both	 control	 cells	 and	 in	 cells	 overexpressing	NFATc2,	 but	 remained	without	 effect	 in	
CMK‐VIVIT	cells,	which	are	unable	to	activate	NFAT	(figure	5.9B,	white	and	black	bars).	
In	 the	 presence	 of	 CsA,	 apoptosis	 induction	 by	 ionomycin	 was	 markedly	 suppressed	
(figure	 5.9B,	 lined	 bars),	 re‐emphasizing	 the	 role	 of	 calcineurin	 in	 this	 process.	
Altogether,	these	data	suggest	that	induction	of	apoptosis	in	MKs	by	calcium/calcineurin	
is,	at	least	partially,	dependent	on	NFAT	activation.	
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Figure	5.9.	Apoptosis	induction	in	megakaryocytes	is	mediated	by	NFAT.	CMK	cells	
were	 retrovirally	 transduced	with	 vectors	 encoding	 either	 NFATc2‐EGFP,	 the	 specific	
inhibitor	of	NFAT	activation	VIVIT,	or	EGFP	control.	The	cells	were	sorted	for	uniform	
expression	of	the	transgene	and	then	either	 left	unstimulated	or	stimulated	with	1	µM	
ionomycin	 (Iono)	 for	 24	h.	Where	 indicated,	 1µM	 cyclosporine	A	 (CsA)	was	 added	30	
minutes	prior	to	the	stimulation.	The	apoptosis	rate	in	each	population	was	quantified	
by	(A)	scoring	1000	DAPI‐stained	nuclei	for	apoptotic	features	(compare	figure	5.8A)	or	
(B)	by	flow	cytometric	analysis	of	annexin	V‐APC/7AAD‐labelled	cells	(compare	 figure	
5.8C).	Shown	are	means	±SEM	from	three	independent	experiments.	*P<0.05.		
			
5.2.4 NFAT induces expression of FASLG protein in megakaryocytes 
 
Fas	and	its	ligand	(FASLG)	are	a	pair	of	trans‐membrane	proteins	critically	involved	in	
apoptosis.	Fas	is	expressed	in	many	types	of	tissues,	whereas	FASLG	expression	is	more	
restricted.176		FASLG	expression	is	predominantly	found	in	activated	T	cells.	However,	its	
expression	is	also	reported	in	other	cells	inside	and	outside	of	the	immune	system,	such	
as	in	NK	cells,	macrophages	and	Sertoli	cells	in	the	testis.177‐179		NFAT	is	well	known	to	
regulate	gene	transcription	and	cytokine	production	in	T	cells	and	various	other	tissues.	
FASLG	is	one	of	the	genes	established	as	transcriptional	target	of	NFAT	in	T	cells.28,	 180		
Interestingly,	 FASLG	was	 also	 established	 as	 the	 first	NFAT	 target	 gene	 in	MKs	 at	 the	
mRNA	 level.79	 However,	 the	 biological	 role	 of	 FASLG	 expression	 by	 NFAT	 in	 MKs,	 is	
largely	unknown.	
Prompted	 by	 our	 observation	 that	 apoptosis	 induction	 in	 MKs	 is	 mediated	 by	 the	
calcineurin/NFAT	 pathway	 (figures	 5.8,	 5.9),	 we	 analyzed	 the	 expression	 of	 FASLG	
protein	in	these	cells.	As	shown	in	figure	5.10,	FASLG	was	undetectable	by	Western	blot	
in	 both	 untreated	 culture‐derived	 primary	 MKs	 and	 CMK	 cells.	 Treatment	 with	
ionomycin	strongly	induced	the	expression	of	FASLG	protein	in	both	cell	types	in	a	time‐
dependent	manner.	Expression	of	FASLG	protein	was	detectable	as	early	as	four	to	six	h	
after	 ionomycin	 stimulation	 and	 followed	 a	 transient	 pattern,	 most	 likely	 because	
membrane‐bound	 FASLG	 is	 shed	 from	 the	 cell	 surface	 by	 the	 action	 of	 matrix	
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metalloproteinases.181,	182	Induction	of	FASLG	expression	by	ionomycin	was	mediated	by	
calcineurin,	 as	 it	 was	 completely	 blocked	 when	 the	 cells	 were	 pretreated	 with	 CsA	
(figure	 5.10A).	 We	 then	 compared	 the	 expression	 of	 FASLG	 in	 CMK	 cells	 stably	
transduced	with	either	EGFP	(control),	NFATc2	or	VIVIT	(figure	5.10B).	After	ionomycin	
stimulation,	 CMK	 cells	 overexpressing	 NFATc2	 showed	 considerably	 higher	 levels	 of	
FASLG	 protein	 than	 control	 cells,	 while	 FASLG	 expression	 in	 CMK‐VIVIT	 cells	 was	
reduced.	These	results	indicate	that	the	expression	of	FASLG	in	MKs	is	strongly	induced	
by	the	calcium/calcineurin	pathway	and	is	dependent	on	the	activation	of	NFAT.	
	
	
 
Figure	 5.10.	 Activation	 of	 calcineurin/NFAT	 in	 megakaryocytes	 induces	 the	
expression	 of	 FASLG.	 (A)	 Ex	 vivo	 differentiated	 primary	 MKs	 were	 either	 left	
unstimulated	or	stimulated	with	1	µM	ionomycin	(Iono)	for	6	and	12	h	in	the	presence	
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or	 absence	 of	 CsA.	 Jurkat	 cells	 stimulated	with	 PMA/ionomycin	 for	 4	 h	were	 used	 as	
positive	control.	(B)	CMK	cells	 stably	 transfected	with	NFATc2,	VIVIT	or	EGFP	control	
were	either	left	unstimulated	or	stimulated	for	the	indicated	time	points	(hours)	with	1	
µM	 ionomycin.	 (A,	 B)	 Total	 protein	 isolated	 from	 the	 cells	 was	 analysed	 for	 FASLG	
expression	(37	KDa)	by	western	blotting.	ß‐actin	was	used	as	loading	control.			
 
 
5.2.5 FASLG is located on the cell surface 
 
Although	 transcription	 and	 translation	 of	 FASLG	 is	 central	 for	 its	 appropriate	
expression,	 increasing	 evidence	 shows	 that	 FASLG	 is	 also	 regulated	 at	 a	 post‐
translational	level.		
Cell	surface	FASLG	cleavage	by	matrix	metalloproteinases	is	one	of	the	mechanisms	that	
provides	 an	 efficient	 mechanism	 for	 limiting	 its	 apoptosis‐inducing	 activity.	
Furthermore,	 in	 order	 to	 exert	 its	 pro‐apoptotic	 effect,	 the	 FASLG	 protein	 has	 to	 be	
localized	on	 the	membrane	of	 the	effector	cell	and,	 for	maximum	Fas	receptor	contact	
and	 cell	 death‐inducing	 potency,	must	 be	 localized	within	membrane	 rafts.182,	 183	 	We	
therefore	analyzed	the	localization	of	FASLG	induced	by	ionomycin	treatment	in	MKs	by	
two	 different	 methods	 (figure	 5.11).	 First,	 CMK	 cells	 were	 stained	 with	 an	 antibody	
against	 FASLG	 and	 analyzed	 by	 flow	 cytometry	 (figure	 5.11A).	 An	 increase	 in	
membrane‐bound	 FASLG	 was	 observed	 after	 stimulation	 with	 ionomycin	 in	 the	
presence	 of	 a	 metalloproteinase	 inhibitor	 (MPi),	 which	 prevents	 shedding	 of	 FASLG	
from	 the	 cell	 surface.	 Second,	 we	 investigated	 the	 cellular	 localization	 of	 FASLG	 in	
culture‐derived	 primary	 MKs	 under	 unstimulated	 and	 stimulated	 conditions	 by	
fluorescence	microscopy	(figure	5.11B,	C).	An	anti‐CD61	antibody	was	used	as	a	specific	
surface	marker	 for	MK	differentiation.	 In	 these	 experiments,	 a	preferential	membrane	
localization	of	FASLG	was	observed	in	ionomycin‐stimulated	MKs,	as	opposed	to	diffuse	
staining	in	unstimulated	cells	(figure	5.11B,	 left	panels,	second	and	third	rows).	Figure	
5.11C	shows	the	distribution	of	the	fluorescence	signal	in	a	representative	indicator	cell,	
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in	which	a	shift	of	the	FASLG	staining	(red	line)	from	a	diffuse	pattern	in	unstimulated	
cells	(upper	panel)	to	a	pattern	localized	in	membrane	proximity	in	stimulated	cells		
(lower	panel)	is	apparent.	These	results	show	that	FASLG	induced	by	calcineurin/NFAT	
activation	in	MKs	is,	at	least	temporarily,	localized	at	the	cell	surface	and	therefore	may	
be	involved	in	the	induction	of	apoptosis	in	bystander	cells.	
Results	
	
	
64	
	
 
	
	
	
Figure	5.11.	FASLG	induced	by	calcineurin/NFAT	activation	in	megakaryocytes	is	
located	on	 the	 cell	 surface.	 (A)	 CMK	 cells	were	 either	 left	 unstimulated	 (grey	 solid	
line)	 or	 stimulated	 with	 1	 µM	 ionomycin	 (black	 fill)	 for	 6	 h	 in	 the	 presence	 of	 a	
metalloproteinase	 inhibitor	 (MPi)	 to	 prevent	 shedding	 of	 FASLG	 from	 the	 surface.	
Expression	of	FASLG	on	the	surface	of	the	cells	was	detected	by	flow	cytometry	using	an	
anti‐FASLG	 antibody.	 Dashed	 line,	 isotype	 control.	 (B)	 Ex	 vivo	 differentiated	 primary	
MKs	were	either	left	unstimulated	or	stimulated	with	1	µM	ionomycin	(Iono)	for	12	h	in	
the	 presence	 or	 absence	 of	 CsA.	 Cytospin	 preparations	 of	 the	 cells	were	 analyzed	 for	
FASLG	 subcellular	 localization	 (red)	 by	 immunofluorescence	 staining.	 DAPI	
counterstaining	(blue)	was	applied	to	visualize	the	nuclear	morphology	of	each	cell,	and	
CD61	(green)	was	used	as	megakaryocytic	differentiation	marker.	Scale	bars	represent	
10	µm.	(C)	Single	cell	fluorescence	analysis	of	culture‐derived	MKs	(FASLG‐DAPI	merge)	
treated	 as	 in	 (B).	 Note	 the	 diffuse	 staining	 pattern	 of	 FASLG	 (red)	 in	 untreated	 cells	
(upper	panel),	as	opposed	to	the	localized,	high	intensity	staining	in	proximity	to	the	cell	
membrane	in	stimulated	cells	(lower	panel).	Shown	(A,	B	and	C)	are	representatives	of	
at	least	three	independent	experiments.		
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5.2.6 The Fas/FASLG pathway is involved in calcineurin/ NFAT-mediated 
apoptosis induction in megakaryocytes 
 
	As	shown	in	the	previous	experiments,	activation	of	the	calcineurin/NFAT	pathway	in	
MKs	 induces	 apoptosis	 and,	 at	 the	 same	 time,	 cell	 surface	 expression	 of	 the	 pro‐
apoptotic	 FASLG	 protein.	 In	 addition,	 MKs	 constitutively	 express	 Fas,	 the	 FASLG	
receptor.184	 To	 determine	 if	 ionomycin‐induced	 programmed	 cell	 death	 in	 MKs	 was	
mediated	 by	 the	 Fas/FASLG	 pathway,	 we	 tested	 the	 effect	 of	 NOK‐1	 and	 ZB4,	 two	
neutralizing	 antibodies	 directed	 against	 FASLG	 and	 Fas	 respectively.	 Both	 antibodies	
interrupt	 the	 binding	 of	 FASLG	 to	 the	 Fas	 receptor	 and	 thereby	 inhibit	 Fas/FASLG‐
mediated	 signaling.	 Culture‐derived	 primary	 MKs	 (figure	 5.12A,	 B)	 and	 CMK‐NFATc2	
cells	(figure	5.12C)	were	 left	unstimulated	or	 treated	with	1	µM	ionomycin	for	24	h	 in	
the	presence	or	absence	of	NOK‐1	or	ZB4.	The	rate	of	annexin	V‐positive	apoptotic	cells	
was	 monitored	 by	 flow	 cytometry.	 As	 shown	 in	 Fig	 5.12,	 both	 antibodies	 inhibited	
(albeit	 incompletely)	 apoptosis	 induction	 by	 ionomycin	 treatment	 in	 these	 cells,	
suggesting	that	the	Fas/FASLG	pathway	is	involved	in	this	process.	
Results	
	
	
66	
	
	
	
Figure	 5.12.	The	 Fas/FASLG	 pathway	 is	 involved	 in	 calcineurin/NFAT‐mediated	
apoptosis	 induction	 in	megakaryocytes.	 Ex	 vivo	 differentiated	 primary	MKs	 (A,	B)	
and	CMK	cells	overexpressing	NFATc2	(C)	were	either	 left	unstimulated	or	stimulated	
with	 1	 µM	 ionomycin	 (Iono)	 for	 24	 h	 in	 the	 presence	 or	 absence	 of	 neutralizing	
antibodies	 against	 Fas	 (ZB4)	 or	 FASLG	 (NOK‐1),	 as	 indicated.	 The	 apoptosis	 rate	was	
determined	 by	 flow	 cytometric	 analysis	 of	 annexin	 V‐positive	 cells.	 (B,	 C)	 Statistical	
analysis	of	at	least	three	independent	experiments	as	in	(A).	Shown	are	means	±	SEM.		
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5.2.7	 Calcineurin/NFATc2‐dependent	FASLG	expression	in	megakaryocytes	
induces	apoptosis	in	(Fas‐positive)	bystander	cells	
	
	In	 addition	 to	 their	 role	 as	producers	of	 platelets,	MKs	 are	known	 to	 express	various	
membrane‐bound	 proteins	 with	 immunomodulatory	 properties	 (e.g.,	 TRAIL,	 CD40	
ligand,	FASLG),	but	the	functional	significance	of	this	phenomenon	is	poorly	understood.	
To	determine	 if	MKs	 are	 able	 to	 induce	 apoptosis	 in	 lymphocytes,	we	 employed	 a	 co‐
culture	system	in	which	CMK	cells	were	first	prelabeled	with	CFSE,	then	were	either	left	
untreated	or	stimulated	with	ionomycin	for	6	h	to	induce	maximal	expression	of	FASLG,	
and	finally	were	mixed	with	Fas‐expressing	Jurkat	T	cells	in	an	effector‐to‐target	ratio	of	
10:1	(figure	5.13).	After	a	co‐incubation	period	of	20	h,	the	apoptosis	rate	in	Jurkat	cells	
was	determined	on	a	single‐cell	basis	by	flow	cytometric	analysis	(figure	5.14B).	CFSE‐
positive	 CMK	 effector	 cells	 were	 gated	 out	 (figure	 5.14,	 upper	 dot	 blot).	 We	 first	
confirmed	 that	 Jurkat	 cells	 were	 susceptible	 to	 Fas‐mediated	 apoptosis	 induction	
(positive	control).	This	was	indeed	the	case,	as	incubation	of	Jurkat	cells	with	CH11,	an	
agonistic	anti‐Fas	antibody,	strongly	increased	the	rate	of	apoptosis	(figure	5.14A).	We	
then	tested	the	effect	of	co‐incubation	of	CMK	cells	on	apoptosis	induction	in	Jurkat	cells.	
To	 assess	 the	 effect	 of	 NFAT,	 CMK	 cells	 overexpressing	 NFATc2	 (CMKNFATc2)	 were	
compared	as	effector	cells	to	CMK	cells	expressing	VIVIT	(compare	left	and	right	panels	
in	figure	5.14B).	As	shown	in	figure	5.14B	(panels	i–iii)	and	figure	5.14C,	the	presence	of	
ionomycin‐prestimulated	 CMKNFATc2	 cells	 in	 the	 co‐culture	 induced	 apoptosis	 in	 Jurkat	
cells	at	a	significant	higher	rate	compared	 to	 the	same	cells	without	prestimulation	or	
cells	 prestimulated	 with	 ionomycin	 in	 the	 presence	 of	 CsA.	 In	 contrast,	 ionomycin	
stimulation	in	CMKVIVIT	cells	remained	without	effect	(figure	5.14B,	panels	v–vi,	and	figure	
5.14D),	 suggesting	 that	NFAT	 is	 involved	 in	 this	 process.	 To	 confirm	 that	 induction	of	
apoptosis	 in	 Jurkat	 target	cells	by	stimulated	CMK	effectors	was	mediated	through	the	
Fas/FASLG	pathway,	CMK/Jurkat	co‐cultures	were	performed	in	the	presence	of	either	
ZB4	 (figure	 5.14B,	 panel	 iv)	 or	 NOK‐1	 (figure	 5.14E).	 Both	 antibodies	 completely	
blocked	apoptosis	 induced	 in	 Jurkat	 cells	by	 stimulated	CMK	cells.	These	data	 suggest	
that	 under	 certain	 conditions	 MKs	 are	 capable	 of	 inducing	 apoptosis	 in	 Fas‐bearing	
bystander	cells,	for	example	lymphocytes.	This	process	is	dependent	on	the	activation	of	
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the	 calcineurin/NFAT	 pathway	 and	 the	 consecutive	 expression	 of	 FASLG	 on	 the	 MK	
membrane.	
	
	
	
	
	
Figure	 5.13.	 Schematic	 representation	 of	 CMK/Jurkat	 co‐cultures.	 CMK	 cells	
(effectors)	were	first	prelabeled	with	CFSE	and	then	remained	either	untreated	or	were	
stimulated	 with	 1	 µM	 ionomycin	 in	 the	 presence	 or	 absence	 of	 CsA	 for	 6	 h.	 After	
washing,	 the	 cells	were	 then	mixed	with	 Jurkat	 cells	 (targets)	 in	 an	 effector‐to‐target	
ratio	(E:	T)	of	10:1.	After	20	h	of	co‐incubation,	 the	cells	were	harvested,	stained	with	
annexin	 V/7AAD,	 and	 the	 apoptosis	 rate	 of	 the	 Jurkat	 cells	 was	 analysed	 by	 flow	
cytometry.		
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Figure	 5.14.	 Calcineurin/NFAT‐induced	 FASLG	 expression	 in	 megakaryocytes	
induces	 apoptosis	 in	 T	 lymphocytes.	 (A)	 Jurkat	 cells	 (mono‐culture)	 were	 left	
untreated	 or	 treated	 with	 an	 activating	 anti‐Fas	 antibody	 (CH11)	 in	 the	 presence	 of	
absence	of	a	neutralizing	anti	Fas	antibody	(ZB4).	The	apoptosis	rate	was	determined	by	
flow	cytometric	analysis	of	annexin	V‐positive	cells.	(B–E)	CMK	cells	stably	transfected	
with	 either	NFATc2	 (CMKNFATc2)	 or	VIVIT	 (CMKVIVIT)	were	 first	 labeled	with	CFSE	 and	
then	either	left	untreated	or	stimulated	for	6	h	with	1	µM	ionomycin	in	the	presence	or	
absence	of	CsA,	as	indicated.	The	prelabeled	and	prestimulated	cells	were	then	washed	
and	co‐incubated	with	Fas‐expressing	Jurkat	T	cells	for	20	h,	after	which	the	apoptosis	
rate	 of	 Jurkat	 cells	 was	 analyzed	 by	 flow	 cytometry	 (see	 figure	 5.13	 for	 a	 schematic	
representation	of	 the	experimental	design).	Note	 that	CFSE‐positive	CMK	effector	cells	
were	 gated	 out	 of	 the	 analysis	 (figure	 5.14B,	 top	 dot	 blot).	 Where	 indicated	 (figure	
5.14B,	 panel	 iv;	 figure	 5.14E),	 co‐cultures	 were	 performed	 in	 the	 presence	 of	
neutralizing	 antibodies	 against	 Fas	 (ZB4)	 or	 FASLG	 (NOK‐1).	 (B)	 Dot	 blots	 represent	
Jurkat	 cells	 after	 20	 h	 of	 co‐culture	with	 CMKNFATc2	 or	 CMKVIVIT	 cells,	which	 had	 been	
pretreated	as	indicated	in	the	respective	panel.	(C–E)	Statistical	analysis	of	at	least	three	
independent	 experiments	 as	 in	 figure	 5.14B.	 Results	 are	 shown	 as	 means	 ±	 SEM.	
*P<0.05,	**P<0.001.		
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5.3	 NFATc2	target	genes	in	megakaryocytes	
	
We	 demonstrated	 for	 the	 first	 time	 that	 the	 expression	 of	 FASLG	 protein	 in	 MKs	 is	
induced	by	NFAT	signaling,	 and	we	extended	 this	 finding	 to	a	 functional	 level,	 i.e.,	 the	
induction	 of	 apoptosis	 in	 bystander	 cells	 mediated	 by	 NFATc2‐induced	 FASLG.	 This	
novel	 finding	prompted	us	 to	 look	 for	 further	NFATc2	target	genes	 in	MKs	globally,	 in	
order	to	further	define	the	role	of	NFAT	in	these	cells.	For	this	purpose,	we	performed	
an	 RNA	 sequencing	 study,	 in	 which	 the	 global	 gene	 expression	 profile	 in	 NFATc2‐
expressing	(WT)	and	–deficient	(KO)	MKs	was	compared.	
	
5.3.1 Generation	of	ex	vivo	pure	and	intact	murine	megakaryocytes		
	
MKs	can	be	 isolated	from	the	BM	or	spleen	of	adult	mice,	but	they	are	rare.	Moreover,	
the	 isolation	of	murine	MKs	by	elutriation	or	cell	 sorting	has	 resulted	 in	poor	yield	of	
intact	 cells,	 and	 such	 cell	 populations	 are	 not	 sufficiently	 pure	 which	 limits	 their	
application	 in,	 for	 example,	 RT‐PCR	 analysis	 of	 gene	 expression	 at	 the	mRNA	 level.66	
However,	 expansion	 and	 differentiation	 of	 MK	 progenitors	 is	 possible	 due	 to	 the	
discovery	of	thrombopoietin	(TPO)	as	a	growth	factor,	which	promotes	lineage‐specific	
differentiation	and	allows	to	obtain	sufficient	cell	numbers.185			
First,	it	was	necessary	to	modify	our	ex	vivo	differentiation	system	that	we	carried	out	in	
human	MKs	(section	5.2),	because	of	the	very	low	number	of	cells	that	can	be	obtained	
from	mice.	To	obtain	a	pure	population	of	intact	and	mature	murine	MKs	and	to	remove	
contaminating	non‐MK	cells,	 the	BM	cell	suspension	was	enriched	 for	 lineage‐negative	
cells	 using	 immunomagnetic	 beads	 conjugated	 to	 an	 anti‐lineage+	mAb	 cocktail	 before	
initiating	 the	ex	vivo	 differentiation	 culture.	 Lineage‐negative	 cells	were	 then	 cultured	
for	3‐4	days	with	100	ng/ml	TPO	to	obtain	an	enriched	population	of	MKs.	Efficiency	of	
the	 differentiation	 process	 was	 examined	 by	 the	 morphology	 of	 the	 cells	 (May‐
Grünwald‐Giemsa	 staining,	 figure	5.15)	 as	well	 as	by	 analysis	of	 surface	 expression	of	
megakaryocytic	 differentiation	 markers	 by	 flow	 cytometry	 (data	 not	 shown).	 Typical	
mature	MK	morphology	was	characterized	by	a	significant	increase	in	size;	basophilic		
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cytoplasm	 in	 immature	 cells	which	 turns	 to	 granulated	 and	 acidophilic	 in	mature	 and	
differentiated	 MKs;	 as	 well	 as	 a	 lobular	 and	 polyploid	 nucleus	 and	 a	 demarcated	
membrane.	The	MK‐enriched	culture	was	resuspended	and	gently	overlaid	on	a	density	
gradient	(1.5%	and	3%	BSA)	with	minimal	agitation.	After	30‐45	minutes	of	incubation,	
white	cells	sedimenting	through	the	lower	BSA	phase	can	be	observed	by	eye.	The	upper	
phase	 was	 removed,	 the	 pellet	 resuspended	 and	 analyzed	 for	 purity	 (>95%)	 and	
integrity	 (figure	5.15).	The	MKs	 then	were	appropriate	 to	be	used	 for	 stimulation	and	
RNA	isolation.		
	
	
	
	
Figure	 5.15.	 Differentiation	 and	 isolation	 of	murine	megakaryocytes.	 	 The	 left	
image	illustrates	the	cell	culture	appearance	of	the	 lineage‐negative	fraction	of	murine	
BM	after	2‐3	d	in	the	presence	of	TPO.		Large	cells	represent	immature	and	mature	MKs.		
Cells	were	 then	 loaded	 over	 a	 BSA	 gradient.	 After	 30	minutes	 of	 incubation,	 the	 cells	
reaching	the	bottom	of	the	tube	were	collected	and	stained	with	May‐Grünwald	Giemsa	
(right	image).	Purity	of	MKs	was	determined	by	microscopic	analysis	of	stained	slides.	
	
 
5.3.2 RNA-sequencing (next generation sequencing) experimental design 
 
Since	NFAT	needs	to	be	activated	in	order	to	translocate	to	the	nucleus	and	bind	to	the	
promoter	of	 its	 target	genes,	 for	differential	expression	analysis	of	 this	study	we	were	
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interested	 in	 comparison	 between	 untreated	 and	 ionomycin‐treated	 murine	 MKs	
isolated	 from	 WT	 and	 NFATc2‐KO	 mice.	 RNA‐Seq	 was	 performed	 on	 six	 biological	
replicates	in	each	group	(untreated	WT	[WT],	untreated	KO	[KO],	ionomycin‐treated	WT	
[WTst],	and	ionomycin‐treated	KO	[KOst]).	
	
	
5.3.3	 Primary	analysis:	Bioinformatics	and	statistical	analysis	 (performed	
by	bioinformaticians)	
	
Before	 performing	 differential	 expression	 tests,	 sequences	 generated	 from	 RNA‐Seq	
experiment	 should	 be	mapped	 to	 libraries	 of	 known	exons	 in	 known	 transcripts.	 This	
step	is	absent	 in	microarray	expression	analysis.	Moreover,	some	basic	statistical	 tests	
such	 as	 correlation	 of	 samples	 and	 variance	 estimation	 are	 necessary	 to	 evaluate	 the	
accuracy	 of	 experimental	 design	 and	 data	 analysis	 process.	 An	 overview	 of	 primary	
analysis	is	presented	below:	
	
	
5.3.3.1	 Mapping	
	
Millions	 of	 reads	were	 generated	 by	 single	 end	 sequencing	 from	 24	 cDNA	 libraries	 –
comprising	 four	 different	 sample	 classes	 ("WT",	 "WTst",	 "KO",	 "KOst")	 –	 with	 6	
replicates	each.	A	range	of	73%‐79%	of	the	sequenced	reads	were	successfully	mapped	
to	the	murine	reference	genome	(mm9	transcriptome).		
	
	
	
5.3.3.2 Correlation	of	the	samples		
	
Correlation	 (sample‐to‐sample	 linear	 dependence)	 between	 each	 two	 samples	 was	
calculated	 (figure	5.16).	 "The	 correlation	 coefficient	 ranges	 from	−1	 to	1.	A	 value	of	 1	
implies	that	a	linear	equation	describes	the	relationship	between X and Y perfectly,	with	
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all	data	points	lying	on	a		line for	which	Y increases	as X increases.	A	value	of	−1	implies	
that	all	data	points	lie	on	a	line	for	which Y decreases	as X increases.	A	value	of	0	implies	
that	 there	 is	 no	 linear	 correlation	 between	 the	 variables"	 (adapted	 from	 Wikipedia;		
http://en.wikipedia.org/wiki/Pearson_product‐moment_correlation_coefficient).	 Figure	
5.16	shows	the	correlation	coefficient	of	~1	(0.97‐0.99)	calculated	for	all	samples.		The	
results	 strongly	 show	 that	 these	 experiments	 are	 accurately	 designed	 and	 are	 highly	
reproducible.	
	
	
	
Figure	5.16.	Correlation	of	 the	 samples.	Correlation	 plot	 together	with	 coefficients	
(numbers)	 for	 all	 samples	 (on	 log	 scale).	 ***	 indicates	 significant	 linear	 correlation	
between	samples.	Red	line	presents	linear	regression.	
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5.3.3.3	 Variance	estimation	
	
To	 check	 the	 dispersion	 among	 the	 replicates,	 variance	 estimation	 was	 performed.	
Typically,	 many	 of	 the	 values	 below	 the	 red	 curve	 are	 underestimates	 of	 the	 true	
dispersions,	so	DESeq	biostatistics	package	uses	the	fitted	values	for	them.	However,	not	
all	values	above	the	red	curve	are	overestimates,	so	the	conservative	choice	 is	to	keep	
them	(instead	of	using	 the	 fitted	values).	Figure	5.17	contains	 the	variance	estimation	
plots	 for	all	conditions	("WT",	 "WTst",	 "KO",	"KOst")	and	 indicates	how	the	expression	
value	of	biological	replicates	are	distributed	(how	far	the	expression	values	lie	from	the	
mean	 value).	 The	 less	 biological	 samples	 are	 used,	 the	 higher	 is	 the	 scattering	 of	 the	
estimates	around	the	true	values.	
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Figure	5.17.	Variance	estimation	plots	for	all	conditions.	Empirical	(black	dots)	and	
fitted	(red	 line)	dispersion	values	plotted	against	mean	expression	level	(log	scale)	 for	
all	 conditions:	 WT,	 KO,	 WTst,	 KOst.	 Dispersion	 is	 calculated	 by	 the	 square	 of	 the	
coefficient	 of	 biological	 variation	 (e.g.,	 if	 a	 gene's	 expression	 differs	 from	 replicate	 to	
replicate	by	20%,	its	dispersion	is	0.20^2	=	0.04).	
	
	
	
5.3.4	 Secondary	 analysis:	 Genes	 of	 interest	 (significantly	 differentially	
expressed	NFATc2	target	genes).		
	
l	
To	 test	 for	 differential	 expression,	 we	 did	 the	 following	 comparisons	 among	 four	
experimental	conditions	using	R	statistical	package	DESeq	(plots	 in	 figure	5.18,	 	 figure	
5.19	and	table	5.2):	
_	resigDEMK1:	WT	vs.	WTst	
_	resigDEMK2:	WT	vs.	KO	
_	resigDEMK3:	KO	vs.	KOst	
_	resigDEMK4:	WTst	vs.	KOst	
First,	 we	 calculated	 the	 number	 of	 significantly	 differentially	 expressed	 genes	 in	
resigDEMK1	and	resigDEMK2,	which	resulted	in	6161	and	22	genes,	respectively.	Then,	
significantly	 differentially	 expressed	 genes	 were	 analyzed	 in	 comparison	 of	 WTst	 vs.	
KOst	(resigDEMK4),	which	resulted	in	592	genes.	
NFAT	is	a	 transcription	 factor,	which	 is	 inactive	without	stimulation	(see	 introduction,	
section	 2.1).	 Genes	 regulated	 by	NFAT	 therefore,	 are	 not	 expected	 to	 be	 expressed	 at	
considerable	 levels	 in	 unstimulated	 samples	 (WT	 and	 KO).	 As	 "genes	 of	 interest"	
therefore	 were	 those	 genes	 considered	 which	 appear	 in	 resigDEMK4	 but	 not	 in	
resigDEMK2,	because	genes	differentially	expressed	between	unstimulated‐WT	and	‐KO	
samples	most	likely	represent	artefacts	(for	example,	unspecific	consequence	of	a	gene	
knockout).	 Finally,	 to	 confirm	 the	 accuracy	 of	 the	 presumed	 “genes	 of	 interest”,	 we	
analyzed	 if	 they	 also	 appeared	 in	 resigDEMK1	 (i.e.,	were	 upregulated	 by	 stimulation).	
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492	of	 580	 genes	 showed	 the	 same	behavior,	 and	 the	 rest	was	 excluded	 from	 further	
analysis	(table	5.2	displays	a	summary	of	differentially	expressed	results).	
	
	
	
	
	
	
Figure	 5.18.	 Plots	 of	 the	 significantly	 differentially	 expressed	 (DE)	 genes.	
Differentially	 expressed	 genes	 were	 obtained	 by	 plotting	 "log2	 fold	 change"	 against	
"normalized	mean	expression	level".	Red	dots	represent	significantly	DE	genes.	WT	vs.	
WTst,	 6161	 significantly	DE	genes.	WT	vs.	KO,	 22	 significantly	DE	genes.	KO	vs.	KOst,	
4327	significantly	DE	genes	and	WTst	vs.	KOst,	592	significantly	DE	genes.		
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Figure	5.19.	Schematic	representation	of	the	analysis	procedure	for	the	selection	
of	differentially	expressed	genes	(DEGs).	
	
	
Comparison	 DEGs	
resigDEMK1:	WT	vs.	WTst	 6161	
resigDEMK2:	WT	vs.	KO	 22	
resigDEMK3:	KO	vs.	KOst	 4327	
resigDEMK4:	WTst	vs.	KOst	 592	
Set	difference	 Different	DEGs	
resigDEMK4‐	resigDEMK2	 580	
OK	genes*	 492	
excluded	genes	 88	
																							*	genes	of	interest	
	
Table	5.2.	Summary	of	differentially	expressed	genes.	 	 The	DEGs	 column	 contains	
the	number	of	significantly	differentially	expressed	genes	at	the	given	comparison.	The	
second	 part	 of	 the	 table	 (set	 difference)	 lists	 the	 number	 of	 "interesting"	 genes	 that	
appear	in	resigDEMK4	but	not	in	resigDEMK2.		Out	of	these	580	"interesting"	genes,	492	
genes	 ("OK	 genes")	 showed	 the	 same	 behavior	 in	 resigDEMK1	 (i.e.,	were	 upregulated	
during	 the	 stimulation	 in	 WT),	 whereas	 88	 genes	 ("excluded	 genes")	 did	 not	 and	
therefore	were	excluded.		
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5.3.4.1	 Confirmation	 of	 results	 by	 known	 NFATc2	 target	 genes	 in	
Megakaryocytes	
	
In	 order	 to	 confirm	 the	 reliability	 of	 the	 final	 list	 of	 genes,	we	 analyzed	 them	 for	 the	
presence	 of	 known	 NFATc2	 target	 genes	 in	 MKs.	 The	 DSCR1	 gene,	 which	 has	 been	
recently	demonstrated	as	an	NFATc2	target	gene	in	MKs,143	was	found	in	the	final	list	of		
"genes	of	 interest"	(an	excerpt	of	the	list	 is	shown	in	figure	5.20A).	In	addition,	a	PCR‐	
array	experiment	using	a	different	 	set	of	samples	of	stimulated/unstimulated	WT	and	
KO	cells	identified	a	number	of	NFATc2‐target	genes	in	MKs	(IGF1,	CD36,	NF‐κB,	ITG‐αm	
and	 ITG‐αv),	 which	 also	 appeared	 in	 the	 list	 of	 RNA‐Seq	 experiment	 (figure	 5.20C).	
These	results	confirm	the	accuracy	and	reliability	of	the	method	and	analysis	procedure	
used	in	this	experiment.	
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Figure	 5.20.	 Confirmation	 of	 RNA‐Seq	 data.	 (A)	 DSCR1	 gene	 (gene	 Ensembl	 ID:	
ENSMUSG00000022951)	 appeared	 in	 the	 list	 of	 "interesting	 gene".	 (B)	 Total	 RNA	
isolated	 from	 either	 WT	 or	 NFATc2‐KO	 murine	 MKs	 were	 analyzed	 for	 DSCR1	 gene	
expression	by	RT‐PCR.	Values	were	normalized	for	expression	of	GAPDH	as	a	reference	
gene	and	expressed	relative	to	the	value	of	the	unstimulated	sample.	(C)	The	expression	
of	IGF1,	CD36,	NF‐κB,	ITG‐αm	and	ITG‐αv	were	evaluated	relative	to	control	sample	by	
PCR‐array.	
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5.3.5    Functional annotation (performed by Miltenyi Biotec Company) 
 
The	functional	grouping	and	annotation	analysis	provides	an	overview	of	 the	different	
biological	processes	and	pathways	that	are	regulated	by	the	provided	gene	set.	The	set	
of	 492	 genes	 was	 subdivided	 into	 an	 upregulated	 group	 (significantly	 differentially	
expressed	 genes,	which	 are	 upregulated	 by	 the	 activation	 of	 NFATc2,	 i.e.,	 in	WTst	 vs.	
KOst)	and	a	downregulated	group.	For	the	functional	annotation	and	grouping	analysis,	
the	 genes	 were	 annotated	 with	 information	 from	 various	 databases	 in	 order	 to	 find	
common	 features	 among	 the	 genes	 sharing	 similar	 expression	 characteristics.	 The	
annotations	used	were	derived	 from	Gene	Ontology	 (GO),	which	provides	 information	
on	molecular	 function,	 as	well	 as	 from	 various	 pathway	 resources	 for	 information	 on	
involvement	in	biological	signaling	pathways.	Subsequently,	the	gene	list(s)	are	used	for	
database	queries	searching	for	annotations	related	to	functional	categories	or	pathway	
membership.	 In	 addition,	 the	 gene	 lists	 obtained	 are	 compared	 to	 known	 targets	 of	
certain	 signaling	 pathways.	 In	 the	 present	 project,	 functional	 grouping	 analysis	 was	
carried	out	for	two	gene	sets	(genes	upregulated	and	downregulated	by	NFATc2).	Table	
5.3	containing	summarized	functional	annotation	results	are	demonstrated.			
This	assessment	cannot	replace	a	full	pathway	enrichment	analysis,	which	uses	a	much	
more	 extensive	 set	 of	 pathways	 and	 biological	 categories.	 In	 the	 present	 analysis,	 the	
upregulated	 gene	 list	 exhibits	 a	 large	 number	 of	 highly	 significant	 associations	 with	
broad	 categories	 such	 as	 innate	 immunity,	 inflammation,	 T‐cell	 immunity,	 B‐cell	
immunity	 and	 with	 more	 specific	 pathways	 like	 cytokine	 signaling,	 NF‐κB	 signaling,	
death‐receptor	signaling,	the	IL‐4,	IL‐6,	wnt	and	TGF‐ß	pathways	(table	5.3).	By	contrast,	
the	 (much	 smaller)	 list	 of	 downregulated	 genes	 does	 hardly	 show	 any	 meaningful	
association	 in	 this	 type	 of	 analysis.	 Obviously,	 a	 more	 fine‐grained	 analysis	 will	 be	
required	to	detect	more	subtle	biological	connections	between	the	regulated	genes.		
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Table	 5.3.	 Pathway	 components	 from	 gene	 ontology	 (GO)	 within	 the	 gene	 set	
upregulated	by	NFATc2.	
Pathway	components(Gene	Ontology)	 No.	of	genes	
	
cytokine/chemokine	signaling	 20	
NF‐κB	signaling	 19	
death	receptor	signaling	 13	
EGF	receptor		 10	
Toll	signaling	 9	
TNF‐α	pathway	 8	
Antigen	presentation	 7	
Wnt	signaling	 7	
Integrin	mediated	signaling	 6	
IL‐4	pathway	 6	
IL‐6	pathway	 6	
B	cell	receptor	pathway	 6	
T	cell	receptor	pathway	 6	
TGF‐ß	signaling	 5	
TGF‐ß	receptor	 5	
IL‐3	pathway	 5	
BMP	signaling	 4	
IL‐1	pathway	 4	
IL‐2	pathway	 4	
PDGF	signaling	 3	
p53	signaling	 3	
hormone/steroid	signaling	 3	
EGF	signaling	 2	
ILGF/insulin	receptor	signaling	 2	
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Further	 analysis	 on	 biological	 pathways	 indicated	 that	 while	 the	 majority	 of	 the	
enriched	categories	are	 indicative	of	an	actively	ongoing	 immune	response	(or	at	 least	
an	activated	state	of	various	immune	cells),	there	are	a	few	enriched	categories	without	
a	direct	 link	 to	 the	 immune	system.	Among	 them	 is	 a	10‐fold	enrichment	of	 the	nitric	
oxide	(NO)	biosynthesis	gene,	Nos2	(encoding	the	inducible	nitric	oxide	synthesis	iNOS).	
Nos2	is	seen	on	the	top	of	the	gene	list	of	enriched	categories	(table	5.4)	that	was	sorted	
by	 the	 transcriptional	 effect	 of	 stimulation	 in	 the	 WT	 cells.	 Ch25h	 (encoding	 a	
cholesterol	 hydroxylase)	 and	 Arg1	 (encoding	 arginase)	 were	 also	 among	 the	 top‐
induced	genes.	Interestingly	both	Nos2	and	Arg1	are	implicated	in	NO	signaling	and	so	
are	 Slc7a2	 (encoding	 an	 arginine	 transporter)	 and	 Cav1	 (encoding	 caveolin‐1),	which	
are	both	highly	induced.		
	
Table	5.4.	Genes	sorted	based	on	the	transcriptional	effect	of	stimulation	in	WT	relative	
to	KO	(only	the	top	twenty	genes	are	shown).	
 
Ensembl	ID	 Gene	
symbol	
effect	
ENSMUSG00000020826  Nos2  10.28 
ENSMUSG00000050370  Ch25h  9.36 
ENSMUSG00000019987  Arg1  9.14 
ENSMUSG00000031596  Slc7a2  7.20 
ENSMUSG00000025321  Itgb8  5.61 
ENSMUSG00000007655  Cav1  5.51 
ENSMUSG00000050578  Mmp13  5.51 
ENSMUSG00000041324  Inhba  5.43 
ENSMUSG00000049511  Htr1b  5.20 
ENSMUSG00000026981  Il1rn  4.85 
ENSMUSG00000074170  Plekhf1  4.80 
ENSMUSG00000028583  Pdpn  4.74 
ENSMUSG00000030162  Olr1  4.60 
ENSMUSG00000053338  Tarm1  4.54 
ENSMUSG00000060044  Tmem26  4.36 
ENSMUSG00000051367  Six1  4.36 
ENSMUSG00000033213  AA467197  4.09 
ENSMUSG00000051439  Cd14  4.04 
ENSMUSG00000035208  Slfn8  3.97 
ENSMUSG00000073489  Ifi204  3.93 
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6	 Discussion		
	
6.1	 Lack	of	 the	 transcription	 factor	NFATc2	 in	hematopoietic	 stem	
cells	results	in	profound	hematological	abnormalities	in	mice	
	
NFATc2	 has	 been	 shown	 to	 be	 expressed	 in	 hematopoietic	 stem	 cells.	 Therefore,	
understanding	 the	 molecular	 mechanisms	 regulated	 by	 this	 transcription	 factor	 is	 of	
importance	and	may	assist	to	exploit	the	NFAT	pathway	for	therapeutic	approaches.	In	
this	study,	we	evaluated	the	role	of	NFATc2	in	hematopoiesis,	using	NFATc2‐/‐	mice	as	a	
model	system.		
We	 have	 previously	 shown	 that	 aged	 mice	 lacking	 the	 transcription	 factor	 NFATc2	
develop	BM	hypoplasia,	 anemia,	 thrombocytopenia	 and	 extramedullary	hematopoiesis	
in	spleen	and	liver.84,	106	The	proliferation	and	differentiation	of	NFATc2‐deficient	HSCs	
ex	vivo,	however,	was	found	to	be	intact.	In	this	study	we	aimed	to	address	the	question	
whether	 the	 disturbed	 hematopoiesis	 in	 NFATc2‐deficient	 mice	 was	 caused	 by	 the	
hematopoietic	or	the	stroma	component	of	the	BM	hematopoietic	niche.	Therefore,	we	
performed	 reciprocal	 transplantation	 experiments	 in	 which	 NFATc2‐/‐	 HSCs	 were	
transplanted	 into	 WT	 mice	 and	 vice	 versa.	 Subsequently,	 post‐transplantation	
alterations	 were	 investigated	 and	 compared	 to	 WT	 and	 KO	 mice	 transplanted	 with	
control	cells.	
	
6.1.1	 HSC	transplantation	
	
At	 present,	 BM	 and	 peripheral	 blood	 hematopoietic	 stem	 cell	 transplantation	 are	
considered	to	be	potentially	 therapeutic	ways	 for	a	variety	of	BM	disorders.	Following	
transplantation,	 HSCs	 are	 able	 to	 reconstitute	 the	 recipient.186	 However,	 the	 use	 of	
whole	BM	as	 a	 source	of	 stem	cells	 includes	 the	 risk	of	 transplantating	 contaminating	
stroma	cells,	which	for	our	experimental	purposes	was	not	suitable.89	
To	 circumvent	 this	 problem,	 Lin‐/Sca‐1+/cKit+	 cells,	 commonly	 referred	 to	 as	 the	 LSK	
compartment	of	HSCs,	are	often	used	for	transplantation.	This	population	has	the	ability	
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to	give	rise	to	hematopoietic	subpopulations	(common	lymphoid	progenitors,	CLP,	and	
common	 myeloid	 progenitors,	 CMP)	 and	 repopulate	 long‐term	 blood‐lineage	 in	
irradiated	 recipients.166,	 168	 Thus,	 we	 employed	 LSK	 cells	 for	 the	 transplantation	
experiments.	
	
6.1.2	 NFATc2	 deficiency	 in	 HSCs	 leads	 to	 hematological	 and	 stroma	
abnormalities	
	
In	 the	 current	 study,	we	demonstrate	 that	 transplantation	 of	NFATc2‐/‐	HSCs	 into	WT	
mice	 leads	 to	 the	 induction	 of	 hematologic	 abnormalities,	 similar	 to	 those	which	 had	
been	 observed	 in	 (non‐transplanted)	 aged	 KO	 mice.	 The	 hematologic	 abnormalities	
were	significant	with	respect	to	the	induction	of	anemia	and	thrombocytopenia	as	well	
as	extramedullary	hematopoiesis	in	spleen	and	liver.	In	addition,	KO	mice	transplanted	
by	WT	HSCs	 demonstrated	 a	 remarkable	 reduction	 in	 the	 hematologic	 abnormalities,	
which	had	been	observed	in	non‐transplanted	KO	mice.	
Hitherto,	 it	 had	 been	 established	 that	 NFATc2	 is	 expressed	 in	 HSCs	 and	 that	 its	
expression	 is	 maintained	 during	 megakaryopoiesis.78,	 79	 In	 contrast,	 it	 had	 not	 been	
described	 as	 a	 crucial	 transcription	 factor	 required	 for	 hematopoiesis.	 In	 mice	 with	
NFATc2	deficiency,	the	hematopoietic	organs	(blood,	BM	and	spleen)	are	abnormal,	but	
the	differentiation	potential	of	HSCs	is	preserved.	
Even	 though	a	 lot	of	evidence	 indicates	 its	 importance	 in	 the	 lifespan	of	HSCs,	 the	BM	
niche	 is	 not	 the	 only	 mechanism	 for	 HSC	 regulation.	 The	 stem	 cell	 itself	 has	 crucial	
impact.	 Fetal	 liver‐derived	 HSCs,	 for	 instance,	 have	 been	 shown	 to	 exhibit	 a	 more	
efficient	regeneration	potential	than	similar	cells	from	adult	BM	when	transplanted	into	
irradiated	 recipients.187	 Bowie	 et	 al	 recently	 revealed	 the	 existence	 of	 “intrinsically	
regulated	master	switch”,	in	which	HSCs	rapidly	change	from	a	fully	cycling	population	
to	a	quiescent	one.188	These	changes	seem	to	be	independent	of	the	niche	as	they	are	not	
affected	by	transplantation	into	adult	recipients.189	
The	BM	of	aged	NFATc2‐deficient	mice	exhibits	hematopoietic	 insufficiencies,	which	 is	
partly	 compensated	 by	 extramedullary	 hematopoiesis	 in	 spleen	 and	 liver.	 The	
observation	 from	 the	 current	 study,	 in	 which	 transplantation	 of	 HSCs	 from	WT	mice	
rescues	 the	 hematological	 abnormalities	 of	 NFATc2‐deficient	 mice	 and	 vice	 versa	
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indicates	that	the	abnormalities	observed	in	the	KO	mice	are	caused	by	an	endogenous	
HSC	defect.	
Supporting	these	data,	there	is	evidence	from	studies	which	indicate	a	role	of	NFAT	in	
cell	 cycle	 and	proliferation.	A	 large	number	of	 genes	 associated	with	 cell	 proliferation	
and	apoptosis	are	induced	by	NFAT.190	In	some	systems,	NFATc2	appears	to	negatively	
control	cell	proliferation,18,	31,	191	since	its	deficiency	(despite	the	presence	of	other	NFAT	
family	 members)	 leads	 to	 uncontrolled	 cell	 growth.	 Contrary	 to	 these	 observations,	
NFATc2	is	known	as	a	regulator	of	apoptotic	mechanisms	by	induction	of	the	expression	
of	a	number	of	pro‐apoptotic	molecules	(e.g.	TNF‐α,	FASLG	and	others).5,	191		Therefore,	
the	role	of	NFATc2	in	proliferation	and	apoptosis	is	complex	and	depends	on	the	cell	and	
the	cellular	context.	
Of	 note,	 the	 hematopoietic	 abnormalities	 induced	 by	 NFATc2‐deficient	 HSCs	 are	
markedly	 apparent	 in	 erythroid	 and	 megakaryocytic	 lineages,	 consistent	 with	 the	
anemia	 and	 thrombocytopenia	 observed	 in	 the	 peripheral	 blood	 of	 NFATc2‐/‐	 mice.		
These	 abnormalities	 are	 rescued	 by	 transplantation	 of	 WT	 HSCs.	 Therefore,	 one	 can	
speculate	 that	 NFATc2	 has	 a	 stronger	 impact	 on	 megakaryocyte‐erythroid	 lineage	
commitment	than	on	other	myeloid	lineages	such	as	granulocyte‐macrophage	lineages.	
However,	 NFATc2	 activation	 is	 not	 required	 for	 erythrocyte	 and	MK	 differentiation.84	
Therefore,	 an	 attractive	 hypothesis	 may	 be	 that	 NFATc2	 mediates	 cell	 cycle	 and	
proliferation	 of	 erythro‐megakaryocytic	 committed	 lineages	 rather	 than	 of	 other	
myeloid	lineages	or	of	lymphocytes.				
Nevertheless,	 the	 phenotype	 observed	 in	 NFATc2‐deficient	 mice	 does	 not	 exclude	 an	
aberrant	 HSC‐stroma	 crosstalk.	 One	 of	 the	 possible	 mechanisms	 might	 be	 perturbed	
homing	caused	by	the	absence	of	NFATc2.	In	order	to	efficiently	establish	hematopoiesis	
after	transplantation,	HSCs	must	home	into	hematopoietic	organs,	especially	the	BM.192,	
193	 We	 tested	 our	 hypothesis	 by	 performing	 homing	 assays,	 in	 which	 hematopoietic	
stem/progenitor	 (lineage‐negative)	 cells	 of	 the	 BM	 were	 isolated	 and	 labeled	 with	 a	
viable	dye	(CFSE).	This	dye	allows	the	detection	of	fluorescent	cells	for	up	to	seven	cell	
divisions,	which	is	adequate	for	the	time	of	homing	(~20	h)	in	our	system.	The	results	
revealed	 no	 differences	 between	 WT	 and	 KO	 HSC	 in	 number	 of	 donor‐derived	
hematopoietic	 stem/progenitor	 cells	 homing	 to	 the	 marrow	 of	 recipient	 mice	 (figure	
5.6).	 These	 results	 could	be	 confounded	by	 the	 fact	 that	 cells	 passing	 through	 the	BM	
intravenous	 system	 may	 be	 miscounted	 as	 “homed	 cells”.	 However,	 some	 studies	
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suggest	 that	 the	 extreme	 adhesion	 capacities	 of	 injected	 stem	 cells	 force	 them	 to	
immediately	 leave	 the	 central	 vein	 and	 reach	 the	 BM	 niche	 within	 a	 few	 hours.194	
Therefore,	in	the	current	experiment,	we	chose	20	h	after	injection	as	the	time	point	for	
the	evaluation	of	homing	cells	in	BM.	Secondly,	we	found	clearance	of	labeled	cells	from	
the	 peripheral	 blood	 of	 the	 transplanted	 mice	 at	 this	 time	 point,	 which	 declines	 the	
possibility	 of	miscalculating	 intravenous	 cells	 as	 cells	 homed	 to	 the	 BM	 niche	 (figure	
5.6C).	Furthermore,	the	fluorescent	intensity	of	engrafted	cells	detected	after	20	h	shows	
the	presence	of	daughter	cells	as	well	as	of	injected	cells	(figure	5.6,	compare	CFSE+	cells	
in	A	and	B)	which	correlates	with	the	fact	that	stem	cells	divide	every	12	h,	and	allows	to	
verify	 the	 appropriate	 time	 of	 detection	 in	 this	 experiment.	 Our	 results	 suggest	 that	
homing	of	NFATc2‐deficient	HSCs	is	normal.	Nevertheless,	due	to	the	limitations	of	the	
experimental	systems	used,	homing	deficiency	cannot	be	excluded	as	mechanism	of	the	
phenotype	 of	 KO	 or	 KOWT	 mice.	 It	 has	 to	 be	 emphasized	 that	 hematopoiesis	 in	
NFATc2‐KO	mice	is	characterized	by	a	“relocation”	of	the	hematopoietic	progenitor	cells	
from	the	BM	to	the	spleen	and	liver	(figure	5.5).	Most	evidence,	therefore,	points	to	the	
hypothesis	that	NFATc2‐deficient	HSCs	suffer	from	a	cell	 intrinsic	defect	which	disturb	
their	interaction	with	the	BM	(but	not	with	spleen/liver)	stroma.	
Homing	 is	 a	 highly	 regulated	 process,93	 in	 which	 the	 expression	 of	 cell	 adhesion	
molecules	 and	 the	 impact	 of	 intrinsic	 and	 extrinsic	 pathways	 which	 mediate	 the	
interaction	 of	 HSCs	 with	 the	 niche	 has	 to	 be	 considered.	 HSC	 engraftment	 has	 been	
shown	 to	 take	place	 in	perivascular	 spaces,195,	 196	which	draws	 the	 focus	on	a	 role	 for	
molecules	 such	 as	 angiopoietin‐1	 receptor	 Tek	 and	 adhesion	molecule	 Integrin‐ß1	 in	
maintenance	and	homing	of	transplanted	HSCs.197	The	expression	of	adhesion	molecules	
or	chemokine	receptors	 in	NFATc2‐deficient	HSC	has	not	been	studied	so	 far	 in	detail,	
but	 may	 be	 a	 focus	 for	 further	 experiments	 in	 the	 future.	 Finally,	 experiments	
monitoring	 the	 proliferation	 of	 transplanted	 HSCs	 in	 vivo	 are	 essential	 to	 be	 also	
considered	in	future	plans.	
Previously,	 we	 have	 shown	 that	 the	marrow	 of	 aged	 KO	mice	 exhibit	 intramedullary	
sclerosis,	 although	 to	 a	 variable	 extent.	The	next	 interesting	question	was	whether,	 in	
addition	to	their	impact	on	hematopoiesis,	donor‐derived	HSCs	are	able	to	transfer	their	
phenotype	to	the	BM	stroma	as	well.	Transplantation	of	KO	HSCs	to	WT	recipients	was	
found	 to	modify	 the	marrow	 structure.	We	 showed	 that	WT	mice	 transplanted	by	KO	
HSCs	 (KOWT)	 (figure	5.3)	demonstrate	 fibrosis	 as	well	 as	ossified	BM	which	 is	 also	
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the	 case	 in	 the	marrow	of	KO	mice	 receiving	KO	HSCs	 (KOKO)	 but	 not	 in	WT	mice	
transplanted	by	WT	HSCs	(WTWT)	(figure	5.3	D,	E).	This	phenomenon	was	however	
incomplete.	 Though	 in	 some	 cases	 of	 KOWT	 mice	 a	 significant	 myelofibrosis	 and	
formation	of	trabeculae	is	observed,	in	others	either	the	modifications	were	moderate	or	
were	not	observed.	We	 reasoned	 that	 these	 symptoms	are	 apparently	 cumulative	 and	
can	be	detected	in	higher	ages.	
This	 phenotype	 of	 NFATc2‐/‐	 mice	 exhibits	 a	 noticeable	 resemblance	 to	 human	
myelofibrosis	(WHO2008:	primary	myelofibrosis).	Myelofibrosis	is	a	myeloproliferative	
disease	 in	 which	 the	 proliferation	 of	 an	 abnormal	 type	 of	 BM	 stem	 cells	 leads	 to	
thrombocytopenia,	 secondary	 intramedullary	 collagen	 fibrosis,	 splenomegaly	 and	
occurrence	 of	 extramedullary	 hematopoiesis.	 To	 date,	 the	mechanisms	 underlying	 the	
secondary	marrow	 changes	 are	 not	 completely	 understood.106,	 198	Mouse	models	with	
overexpression	 of	 TPO	 (TPOhigh	mice)	 or	 low	 expression	 of	 GATA‐1	 (GATA‐1low	mice)	
have	 also	 been	 shown	 to	 exhibit	 myelofibrosis.	 In	 these	 animals,	 a	 significant	
contribution	 of	 transforming	 growth	 factor‐beta	 1	 (TGF‐ß1)	 originating	 from	
hematopoietic	 cells	 was	 found	 to	 induce	 marrow	 fibrosis.	 Other	 factors,	 including	
osteoprotegerin	 (OPG),	 basic	 fibroblast	 growth	 factor	 (bFGF),	 platelet‐derived	 growth	
factor	(PDGF)	and	vascular‐endothelial	growth	factor	(VEGF)	have	also	been	implicated	
in	 mediating	 osteosclerosis,	 fibrosis	 and	 angiogenesis	 in	 this	 disease.	 It	 is	 currently	
assumed	that	various	cytokine	families,	notably	TGF‐ß,	are	associated	with	alterations	in	
MKs.199‐201	 Since	 TPO	 (extrinsically)	 and	 GATA‐1	 (intrinsically)	 both	 control	 MK	
differentiation,	 the	 development	 of	 myelofibrosis	 in	 above‐mentioned	 mouse	 models	
(TPOhigh	 and	 GATA‐1low)	 is	 the	 result	 of	 high	 TGF‐ß	 levels	 originating	 from	 MK	
dysfunction.	The	 similar	phenotypes	observed	 in	NFATc2‐/‐	 and	GATA‐1low	mice	might	
provide	a	clue	to	the	underlying	mechanism.	GATA‐1,	known	as	a	transcriptional	partner	
of	NFAT,	is	established	as	a	regulator	of	megakaryopoiesis	(section	2.4.1	and	figure	2.2).		
NFAT	and	GATA	families	of	transcription	factors	are	shown	to	cooperatively	control	the	
expression	 of	 certain	 genes	 (e.g.	 IL‐4,	 IL‐5	 and	 IL‐13)	 in	 Th2	 (T	 helper	 2)	 and	 mast	
cells.202	 A	 crosstalk	 of	 NFAT	 and	 GATA‐1	 could	 also	 be	 illustrated	 in	 patients	 with	
Down's	 syndrome,	 in	 which	 MK	 dysfunction	 might	 be	 the	 consequence	 of	 the	
combinatorial	 effects	 of	 GATA‐1	 mutation	 and	 NFAT	 inactivation	 caused	 	 by	
overexpression	of	DSCR1	(down	syndrome	critical	 region	1).173	As	a	conclusion,	NFAT	
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and	 GATA‐1	might	 have	 roles	 in	 the	 transcriptional	 regulation	 of	 hematopoietic	 cells	
which	themselves	can	influence	the	stroma	compartment	of	the	BM	as	well.	
At	present,	allogenic	stem	cell	transplantation	is	considered	as	one	of	the	most	efficient	
treatments	 for	 the	 patients	 with	myelofibrosis.203,	 204	 	 An	 interesting	 outcome	 of	 this	
study	also	reveals	that	KO	mice	harboring	myelofibrosis	are	at	least	in	part	rescued	by	
WT‐derived	 HSCs	 (WTKO).	 Conversely,	 myelofibrosis	 is	 induced	 in	 WT	 mice	 by	
transplanting	KO	HSCs	(KOWT).			
These	 findings	 should	promote	more	 investigation	 in	 the	 transcriptional	 regulation	 of	
NFATc2,	 particularly	 in	 the	 erythro‐megakaryocytic	 lineage.	 Of	 particular	 interest	
apparently	are	MKs	since	these	cells	are	involved	in	a	number	of	diseases,	for	instance	
myelofibrosis	 (osteomyelofibrosis)	 which	 is	 observed	 in	 NFATc2‐/‐	 mice	 as	 well.		
Therefore,	these	data	prompted	us	to	investigate	the	role	of	NFATc2	in	MKs.		
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6.2	 NFATc2	regulates	apoptosis	in	megakaryocytes	
	
Signal	transduction	pathways	regulating	gene	expression	in	MKs	are	poorly	understood.	
Studies	 in	 MKs	 are	 complicated	 by	 the	 problem	 of	 their	 low	 abundance	 in	 the	 BM	
(~0.5%)	 and	 the	 difficulties	 in	 obtaining	 sufficient	 numbers	 for	 experiments.185,	 205	
Moreover,	 MKs	 isolated	 by	 these	 methods	 are	 not	 sufficiently	 pure	 and	 intact.	
Researchers	 have	 overcome	 these	 problems	 either	 by	 employing	megakaryocytic	 cell	
lines	or	by	differentiating	MKs	ex	vivo	out	of	their	progenitor	cells.	Megakaryocytic	cell	
lines	 (for	 example,	 CMK,	Meg‐01,	M‐07,	 K562)	 provide	 a	 unique	 opportunity	 to	 study	
MKs.205,	206		However,	they	are	leukemic	cells	with	a	modified	karyotype	and	represent	
an	 immature	 state	 of	 MKs.	 Therefore,	 the	 physiological	 significance	 of	 any	 finding	 in	
these	 systems	 needs	 to	 be	 confirmed	 in	 primary	 cells.	 Thus,	 in	 addition	 to	
megakaryocytic	cell	 lines,	we	considered	it	important	to	confirm	our	principal	findings	
in	 culture‐derived	 primary	 MKs	 (ex	 vivo‐differentiated	 MKs).	 	 The	 availability	 of	
thrombopoietin	 (TPO),	 a	 cytokine	 that	 stimulates	 megakaryopoiesis	 enabled	 us	 to	
expand	 MKs	 efficiently	 ex	 vivo	 for	 research	 purposes.66,	 117	 Therefore,	 MKs	 were	
differentiated	over	several	days	out	of	either	primary	CD34+	hematopoietic	progenitor	
cells	(for	human	MKs)	or	Lin‐	cells	(for	mouse	MKs,	section	6.3)	in	the	presence	of	TPO	
for	our	experiments.	
 
6.2.1	 NFAT	 regulates	 inducible	 FASLG	 protein	 expression	 in	
megakaryocytes	
	
In	 the	 present	 study,	 we	 identify	 the	 phosphatase	 calcineurin	 and	 the	 transcription	
factor	NFAT	as	part	of	a	calcium‐dependent	signal	transduction	pathway	that	is	central	
for	 inducible	 gene	 expression	 in	 MKs.	 From	 earlier	 studies,	 it	 was	 known	 that	 MKs	
express	 both	 calcineurin	 and	NFAT	 proteins,	 and	 that	 the	 expression	 of	 NFAT	 during	
megakaryopoiesis	was	regulated	in	a	lineage‐specific	manner.78,	79	Neither	activation	of	
calcineurin	nor	of	NFAT,	however,	proved	to	be	necessary	for	the	differentiation	of	MKs	
from	 hematopoietic	 progenitor	 cells.142	 We	 then	 focused	 on	 the	 question	 if	 the	
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calcineurin/NFAT	pathway	was	involved	in	the	regulation	of	gene	expression	in	mature	
MKs.	 Indeed,	we	and	others	could	subsequently	 identify	the	CD154,	DSCR1	and	FASLG	
genes	as	NFAT	transcriptional	targets	in	these	cells.79,	126,	143		
The	present	study	for	the	first	time	extended	these	findings	and	advanced	them	from	a	
descriptive	 to	 a	 functional	 level.	 We	 demonstrate	 that	 activation	 of	 the	
calcineurin/NFAT	 pathway	 in	 MKs	 induces	 expression	 of	 the	 FASLG	 protein.	
Immunoblot	 analysis	 revealed	 that	 FASLG	protein,	 in	 stimulated	 ex	vivo	 differentiated	
MKs	as	well	as	in	transfected	megakaryocytic	CMK	cells,	was	detected	within	hours	and	
exactly	 followed	 the	pattern	 of	 its	 expression	 in	 stimulated	 Jurkat	T	 cells.	 Conversely,	
FASLG	protein	expression	was	completely	undetectable,	when	cells	were	stimulated	in	
the	presence	of	calcineurin	inhibitor	CsA,	which	indicates	FASLG	expression	is	mediated	
by	calcineurin.		Since	calcineurin	can	affect	other	pathways	via	different	substrates,	CMK	
megakaryocytic	 cells	 transfected	 with	 NFAT‐specific	 peptide‐inhibitor	 of	 calcineurin	
VIVIT	were	used	and	also	showed	an	inhibition	of	FASLG	protein	expression.	Therefore,	
the	expression	of	FASLG	protein	in	MKs	is	mediated	by	NFAT.		
Similar	to	other	proteins	of	the	TNF‐family,	FASLG	is	also	found	in	two	variants,	namely	
membrane‐bound	FASLG	(molecular	weight	of	37	KDa)	and	soluble	FASLG	(sFASLG,	26‐
29	 KDa).	 It	 has	 been	 shown	 that	 sFASLG	 is	 generated	 by	 proteolytic	 cleavage	 of	
membranous	FASLG	by	matrix	metalloproteinases.207	Tanaka	et	al.	have	demonstrated	
that	 sFASLG	 acts	 to	 prevent	 the	 cytotoxic	 activity	 and	 reduce	 the	 effectiveness	 of	
membrane‐bound	FASLG.181,	208	Therefore,	membranous	FASLG	is	the	functional	form	of	
the	protein.	As	we	show	in	our	study,	NFAT‐mediated	FASLG	protein	in	stimulated	MKs	
is	located	at	the	membrane	of	the	cells.	Fas/FASLG	interaction	is	essential	for	triggering	
programmed	cell	death.	It	has	been	shown	that	functional	FASLG	is	partially	localized	in	
membrane	rafts	and	is	remarkably	increased,	once	it	interacts	with	its	receptor	for	the	
induction	 of	 apoptosis.	 Immunofluorescence	 staining	 of	 FASLG	 demonstrates	 the	
accumulation	 of	 FASLG	 protein	 in	 the	 proximity	 or	 on	 the	membrane	 of	mature	MKs	
when	 the	 calcineurin/NFAT	 pathway	 is	 activated.182,	 183	 These	 findings	 raised	 the	
hypothesis	 that	 FASLG	 protein	 expressed	 via	 calcineurin/NFAT‐mediated	 pathway	
might	be	functional.		
	
		
	
Discussion	
	
93	
	
6.2.2	 Calcineurin/NFAT‐dependent	expression	of	FASLG	in	megakaryocytes	
is	functional		
	
Of	note,	FASLG	expression	is	also	found	in	platelets.209,	210		As	platelets	are	anuclear	cells	
and	receive	 their	genetic	repertoire	 from	their	MK	precursors,	 it	had	to	be	considered	
that	 FASLG	 expression	 in	 MKs	 may	 serve	 the	 sole	 purpose	 to	 transfer	 it	 to	 their	
progeny.126,	 127	 In	addition,	platelets	express	biologically	active	FASLG	on	 their	surface	
which	is	able	to	induce	apoptosis	in	Fas‐positive	cells,	thus	it	was	crucial	to	investigate	
whether	NFAT‐induced	FASLG	protein	in	MKs	is	able	to	exert	biological	activity	as	well.	
One	 of	 the	 main	 findings	 of	 our	 study	 suggests	 that	 FASLG	 expression	 in	 MKs	 is	 of	
intrinsic	biological	significance	for	these	cells.	First,	transcription	of	the	FASLG gene	in	
MKs	 is	 not	 only	 followed	 by	 expression	 of	 the	 protein,	 but	 the	 protein	 is	 also	
appropriately	transported	to	the	MK	surface	(figure	5.11).	Second,	we	demonstrate	that	
expression	of	the	membrane	protein	is	functional,	as	it	conferred	to	the	MK	the	ability	to	
induce	programmed	cell	death	in	bystander	cells	(figures	5.12	and	5.14).		
Of	note,	as	we	demonstrate	 in	this	study,	 the	propensity	of	MKs	to	 induce	apoptosis	 is	
not	a	constitutive	characteristic	of	these	cells,	but	requires	prior	stimulation	with	agents	
that	 increase	 the	 intracellular	 calcium	 to	 levels	 sufficient	 to	 activate	 the	
calcineurin/NFAT	pathway.	We	also	provide	 the	 explanation	 for	 this	observation	on	a	
molecular	level,	as	we	show	that	expression	of	the	FASLG	gene	in	MKs	follows	the	same	
inducible,	calcineurin/NFAT‐dependent	pattern	as	 in	T	 lymphocytes.	The	physiological	
ligand	which	is	capable	to	activate	MKs	in	vivo	is	presently	unknown	and	may	depend	on	
the	 respective	microenvironment.	 Collagen	 (an	 extracellular	matrix	protein	present	 in	
the	BM)	as	well	 as	 thrombin	are	possible	 candidates,	 as	 treatment	of	MKs	with	either	
agent	is	able	to	induce	activation	of	the	calcineurin/NFAT	pathway	in	vitro	and	regulates	
proplatelet	 formation.143	 Furthermore,	 the	majority	of	MKs	 spend	 their	 lifetime	 in	BM	
until	 they	undergo	apoptosis	and	release	platelets	 into	the	blood	stream.	Collagen,	 the	
main	component	of	connective	tissue,	is	abundantly	found	in	the	extracellular	matrix	of	
the	 BM	 microenvironment	 and	 blood	 vessels,	 thus	 it	 is	 possible	 that	 this	 protein	
functions	as	physiological	ligand	for	MK	stimulation.		
It	 has	 been	 observed	 that	 MK	 apoptosis	 and	 proplatelet	 formation	 is	 augmented	 by	
treatment	of	MKs	with	an	agonist	anti‐Fas	antibody	which	 in	 fact	mimics	the	action	of	
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FASLG.184	Interestingly,	our	finding	shows	that	MKs	are	also	able	to	induce	apoptosis	in	
other	MKs.	The	biological	relevance	of	this	phenomenon	is	unknown	and	merits	further	
investigation.	 Practically,	 activation	 of	 the	 Fas/FASLG	 pathway	 between	 MKs	 would	
require	that	they	are	 located	in	close	proximity	to	each	other.	Considering	their	rarity,	
this	is	unlikely	to	occur	during	megakaryopoiesis.	However,	it	has	been	shown	that	some	
cell	 types	 express	 both	 Fas	 and	 FASLG	 concurrently	 that	 could	 potentially	 lead	 to	
autocrine	 cell	 death.211,	 212	 After	 conclusion	 of	 their	 maturation,	 MKs	 are	 known	 to	
migrate	within	the	BM	to	blood	vessels,	where	they	release	their	platelets	in	a	process	
called	 proplatelet	 formation.	 As	 an	 intriguing	 hypothesis,	 MK	 apoptosis	 under	 these	
circumstances	might	be	induced	by	other,	co‐migrating	MKs,	which	had	been	activated	
within	the	BM	vascular	niche	to	upregulate	expression	of	FASLG	on	their	membrane.		
It	 has	 to	 be	 noted,	 however,	 that	 blocking	 antibodies	 against	 Fas	 and	 FASLG	 are	 only	
partially	 able	 to	 suppress	 apoptosis	 induced	 by	 ionomycin	 treatment	 in	 MKs	 (figure	
5.12).	Therefore,	other	pathways	than	Fas/FASLG	probably	contribute	to	the	regulation	
of	apoptosis	in	MKs	as	well.	Possible	candidates	are	members	of	the	Bcl‐2	family,	which	
have	been	identified	to	regulate	programmed	cell	death	in	platelets	in	vivo, possibly by	
inhibiting	 calcineurin	 activation.213	 Overexpression	 of	 Bcl‐2	 for	 instance,	 results	 in	
decreased	 proplatelet	 formation	 and	 lower	 platelet	 counts	 in	 mice,	 whereas	 MK	
numbers	remained	unchanged.214‐216			
Finally,	our	results	suggest	that	MKs	may	be	capable	of	inducing	apoptosis	in	other	Fas‐
bearing	cells,	notably	lymphocytes.	FASLG,	via	interaction	with	its	receptor	Fas,	plays	a	
key	role	in	the	regulation	of	programmed	cell	death,	for	example	in	cells	of	the	immune	
system.	 It	 is	 now	obvious	 that	 the	 cells	 in	 the	BM	are	not	 only	 connected	 in	 terms	of	
proximity	but	by	functionality,	and	it	is	increasingly	recognized	that	MKs,	despite	their	
rarity,	 exert	 biological	 functions	 independent	 from	 their	 role	 as	 platelet	 producers.	
Several	 studies,	 for	 example,	 show	 that	 they	 are	 involved	 in	 the	maintenance	 of	 bone	
homeostasis.217‐219	 They	 produce	 cytokines	 that	 induce	 fibrosis	 in	 the	 BM	 and	 other	
organs	 including	 spleen	 and	 lung.220‐222	 Growth	 factors	 and	 cytokines	 such	 as	 PDGF,	
bFGF	and	TGF‐ß	which	are	produced	by	MKs,	 are	 found	 to	be	 the	major	mediators	of	
increased	reticulin	fibers	in	myelofibrosis	disorders.221,	223	Under	certain	circumstances,	
they	 appear	 in	 blood,	 spleen,	 liver	 and	 lung,	 where	 they	 migrate	 to	 sites	 of	 active	
inflammation.122,	124,	220	For	example,	in	patients	suffering	from	burns	or	in	experimental	
models	of	shock,	an	accumulation	of	MKs	has	been	described	in	the	lung.124		
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Hence,	MKs	 interact	with	 their	microenvironment,	 but	 their	 cellular	 counterparts	 and	
the	mechanisms	of	cellular	interaction	are	incompletely	understood.	In	this	respect,	our	
study	provides	interesting	findings.	The	physiological	relevance	of	Fas/FASLG‐mediated	
apoptosis	 induction	 by	 MKs	 in	 bystander	 cells,	 however,	 needs	 to	 be	 elucidated	 in	
further	studies.	
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6.3 NFATc2	regulates	multiple	genes	in	megakaryocytes	
	
In	order	to	obtain	a	comprehensive	picture	of	the	NFAT	function	in	MKs,	it	is	necessary	
to	discover	other	NFAT	target	genes	in	this	cell	type.	For	the	identification	of	additional	
NFATc2	regulated	genes,	an	RNA‐Seq	analysis	using	ex	vivo	differentiated	murine	MKs	
was	performed.	
Though	 the	 list	of	genes	which	were	dependent	on	 the	presence	of	NFATc2,	was	clear	
and	significant,	at	 the	same	time	 it	was	quite	unexpected.	An	 interesting	finding	was	a	
strong	and	broad	immune‐activation	phenotype	regulated	by	NFATc2,	going	along	with	
the	strong	induction	of	many	genes	involved	in	various	aspects	of	the	immune	response.	
While	 such	 an	 immune‐stimulatory	 effect	would	have	been	 expected	 as	 a	 response	 to	
NFAT	stimulation,	the	genes	involved	in	the	observed	response	do	hardly	overlap	with	
the	canonical	NFAT	target	genes.	Interestingly,	the	pathways	induced	by	the	treatment	
are	mostly	 identical	 to	 the	known	NFAT‐induced	pathways	(IL‐2,	 IL‐4,	 IL‐5,	TNF,	 IFN),	
but	the	observed	transcriptional	regulation	mainly	affects	the	receptors	rather	than	the	
cytokines.	
Another	interesting	finding	of	this	study	was	the	strong	induction	of	genes	involved	in	
nitric	oxide	 (NO)	biosynthesis.	Nos2,	Ch25h,	Arg1,	 Slc7a2	and	Cav1	genes	are	seen	on	
the	 top	 of	 the	 gene	 list	 that	 were	 sorted	 by	 the	 transcriptional	 effect	 of	 ionomycin‐
stimulation	 in	 the	WT	 cells.	 Interestingly,	 four	 out	 of	 six	most	 strongly	 induced	 genes	
have	 a	 role	 in	 NO	 biosynthesis	 from	 arginine.	 This	 pathway	 is	 known	 to	 play	 an	
important	role	in	macrophages,	however,	the	upregulation	factor	of	the	NO	biosynthesis	
genes	 is	 much	 higher	 than	 that	 of	 most	 other	 macrophage‐specific	 markers,	 which	
suggests	that	this	pathway	might	be	important	in	MKs.		
The	 current	 findings	 contribute	 a	 novel	 understanding	 of	 NFAT	 transcriptional	
regulation	in	mature	MKs.	However,	data	validation	by	quantitative	PCR	or	PCR‐array	as	
well	 as	 by	 functional	 assays	 of	 differentially	 expressed	 genes	 is	 still	 necessary	 and	
should	 be	 scheduled	 for	 future	 studies.	 Furthermore,	 these	 data	 represent	 a	 useful	
source	 for	 identification	 of	 new	 regulators	 which	 cooperatively	 work	 with	 NFAT	 in	
different	cellular	processes	of	MKs.	
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7	 Conclusion	
	
The	 NFAT	 transcription	 factors	 are	 primarily	 known	 for	 their	 central	 role	 in	
transcriptional	 regulation	 of	 lymphocytes.	 Recently,	 the	 family	 member	 NFATc2	 has	
been	shown	to	be	expressed	 in	hematopoietic	stem	cells	as	well	as	 in	specific	myeloid	
cell	 types,	 especially	 in	MKs.	 The	 function	 of	 this	 transcription	 factor	 in	 this	 context,	
however,	 was	 unknown.	 The	 aim	 of	 the	 present	 work	 was	 to	 contribute	 to	 the	
understanding	of	the	role	of	NFAT	in	hematopoietic	cells,	with	a	particular	focus	on	MKs.	
	
We	 show	 that	 lack	 of	 NFATc2	 in	 hematopoietic	 stem	 cells	 results	 in	 perturbed	
hematopoiesis	 in	 mice,	 namely	 BM	 hypoplasia,	 peripheral	 blood	 cytopenia	 and	
extramedullary	hematopoiesis.	Our	results	point	to	disrupted	interaction	of	the	NFATc2‐
deficient	 stem	 cell	 with	 its	 BM	 hematopoietic	 niche.	 One	 possible	 mechanism	 is	 an	
inefficient	 homing	 capability	 of	 HSCs,	 but	 this	 could	 not	 be	 experimentally	 proven.	
Alternative	 possibilities	 include	 cell‐intrinsic	 mechanisms	 such	 as	 cell	 cycle	 or	
proliferation,	but	the	ex	vivo	characteristics	of	NFATc2‐/‐	seem	to	be	normal.		
	
While	 the	 activation	 of	 NFATc2	 has	 shown	 to	 be	 dispensable	 for	 megakaryocytic	
differentiation,	 previous	 studies	 had	 suggested	 that	 NFATc2	 plays	 a	 role	 in	 the	
regulation	of	 inducible	 gene	 expression	 in	mature	MKs.	Here,	we	demonstrate	 for	 the	
first	 time	 that	 expression	 of	 the	 Fas	 ligand	 protein	 in	 MKs	 occurs	 in	 an	 inducible,	
calcineurin/NFAT‐dependent	 manner,	 and	 is	 transported	 to	 the	 MK	membrane.	 Most	
importantly,	we	prove	that	Fas	ligand	protein	induced	by	NFAT	signaling	is	biologically	
active	and	able	to	induce	apoptosis	in	Fas‐bearing	bystander	cells.		
Finally,	 we	 have	 identified	 by	 RNA	 sequencing	 analysis	 of	 NFATc2‐expressing	 and	 ‐
deficient	 cells	 the	 entire	 set	 of	 genes	which	 is	 induced	by	NFATc2	 in	 stimulated	MKs.	
Functional	 pathway	 analysis	 suggests	 an	 involvement	 of	NFATc2	 in	 pro‐inflammatory	
pathways	in	these	cells.	The	significance	of	these	findings	has	to	be	addressed	in	further	
studies.	
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8	 Thesis	
	
 NFATc2,	a	member	of	the	NFAT	(Nuclear	Factor	of	Activated	T	cells)	family,	has	a	
biological	 role	 in	 hematopoiesis.	 Lack	 of	 NFATc2	 in	 hematopoietic	 stem	 cells	
leads	to	hematological	and	osteogenic	abnormalities	in	mice.	
	
 Hematopoietic	 stem	 cells	 with	 NFATc2	 deficiency	 are	 able	 to	 transfer	 the	
phenotype	of	aged	NFATc2‐deficient	mice	to	wild	type	mice.	
	
 NFATc2	may	 influence	 the	cross‐talk	between	hematopoietic	stem	cells	and	the	
BM	stroma	cells.	
	
 NFATc2	deficiency	is	associated	with	hematological	abnormalities,	and	therefore	
might	 be	 exploited	 as	 therapeutic	 target	 for	 the	 development	 of	 new	drugs	 for	
treatment	of	hematological	disorders	in	the	future.	
	
 NFATc2	 is	 a	 transcriptional	 regulator	 of	 gene	 expression	 in	 mature	
megakaryocytes.	
	
 Activation	 of	 the	 calcineurin/NFAT‐pathway	 leads	 to	 the	 expression	 of	 the	 Fas	
Ligand	gene	and	subsequently,	its	protein.		
	
 Fas	 Ligand	 protein	 induced	 by	 the	 activation	 of	 calcineurin/NFAT	 pathway	 is	
biologically	 functional	 as	 it	 is	 transferred	 to	 the	membrane	 of	megakaryocytes	
and	is	able	to	induce	programmed	cell	death	in	Fas‐positive	bystander	cells.	
	
 Megakaryocytes	 fulfill	 a	 cell‐intrinsic	 function	which	 is	 independent	 of	 platelet	
production.	They	may	contribute	to	a	number	of	physiological	mechanisms	such	
as	bone	hemostasis	or	inflammation.	
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 Further	 studies	 should	 aim	 to	 investigate	 the	 regulatory	 role	 of	 NFAT	 in	
hematopoiesis,	 in	 hematopoietic	 cells	 of	 various	 lineages	 (specifically	
megakaryocytes)	and	the	stroma	components	of	the	hematopoietic	niche.	
	
 The	 expression	 profile	 of	 genes	 regulated	 by	 NFATc2	 in	 stimulated	
megakaryocytes	 suggests	 a	 role	 of	 this	 factor	 in	 pro‐inflammatory	 conditions.	
The	biological	significance	of	this	finding	has	to	be	verified	in	further	studies.		
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